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‘This is not the end. 
It is not even the beginning of the end. 
But it is, perhaps, the end of the beginning.’ 
 
Winston Churchill, London, 10 November 1942 
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Summary 
HIV/AIDS remains the world’s leading infectious cause of death, despite global 
efforts for prevention and better access to treatment. At the end of 2007, about 33 
million people were living with HIV/AIDS, with nearly 2.5 million newly infected yearly 
and Sub-Saharan Africa being most affected. Although the use of ART has 
significantly reduced HIV-related mortality in the industrialised world, only 28% of 
people in need of ART worldwide, actually have access to it. Global initiatives aiming 
at universal access to ART by 2010 are still ongoing. The expansion of global access 
to ART should remain a priority, yet tools to assess the response to treatment are 
equally important. Assays to quantify the viral burden in plasma and to identify drug 
resistant mutations have become the standard of care to monitor patients on 
treatment in the industrialised world. However, widespread use of these assays in 
resource-limited settings is still hampered by their high cost and the lack of well-
equipped laboratories. Therefore, there is an urgent need to develop and evaluate 
simple and affordable alternatives for the current viral load and resistance assays, 
which can be implemented in resource-limited settings. 
 
Regular viral load measurements are important parameters to detect early treatment 
failure, thereby avoiding the accumulation of drug resistance mutations. They can 
also diagnose perinatal infections and prevent unnecessary treatment switches, by 
monitoring adherence to ART. Moreover, viral load assays could be useful as a 
sentinel surveillance tool in ART program quality assessments. WHO recognises the 
need for viral load assays and advocates the use of simple, inexpensive and 
accurate tools for measuring HIV-1 viral load. Three types of alternative viral load 
assays have been proposed: assays to quantify p24 Ag, assays to measure reverse 
transcriptase activity and in-house real-time PCR assays. The latter two showed the 
most promising results, however little information about performance of these assays 
in a resource-limited setting is available. Therefore we decided to assess the 
usefulness of the ExavirLoad (Cavidi) and Generic HIV viral load (Biocentric) in a 
real-life situation in Mombasa, Kenya. We found a good correlation for both assays 
when compared with the Amplicor HIV-1 Monitor v1.5 assay (Roche), but the 
specificity was less optimal, especially for the ExavirLoad. Both these assays could 
be valuable tools for viral load measurements, yet they have their drawbacks and the 
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choice for the right viral load assay should be made at each site individually, taking 
the specific advantages and disadvantages into account.  
 
The lack of affordable viral load measurements as a parameter to assess early 
treatment failure, will increase the risk of accumulation of resistance mutations 
leading to a high probability of cross-resistance. This will not only pose a problem for 
the individual patient, but it will also increase the risk of transmission of highly 
resistant viruses in the population, jeopardizing future treatment options. There is an 
urgent need for affordable genotypic resistance assays and therefore an in-house 
genotyping assay was evaluated. Due to the high sensitivity of this assay, it allows 
the combined detection of plasma HIV-1 and possible drug resistant mutations, 
reducing the need for standard viral load and genotyping assays. 
Widespread use of viral load testing and genotyping in resource-limited settings, is 
not only hampered by the high cost of these assays but also by the lack of proper 
infrastructure. One of the challenges is to guarantee the cold chain, needed for the 
storage and transportation of blood samples. In this respect our in-house genotyping 
assay was adapted for the use of cellular DNA from whole blood and dried blood 
spots (DBS). Our study showed the feasibility of extracting and subsequently 
sequencing HIV-1 DNA from whole blood and DBS. Although DNA sequencing can 
be useful in epidemiological studies, such as analysing subtype distribution and the 
overall spread of drug resistance mutations, our study confirmed that RNA 
sequencing remains superior over DNA sequencing in the individual follow-up of 
patients, especially at early treatment failure.  
 
The scale-up of ART in low and middle-income countries has been proven 
successful, despite the lack of adequate laboratory assays to monitor patients on 
treatment. Similarly, we found a treatment success rate of 86.2% for those treated for 
at least 6 months at the Comprehensive Care Centre in Mombasa. However, the rate 
of accumulation of resistance mutations among the patients failing treatment is of 
great concern. In our study, 87.5% of the patients with a detectable viral load, 
developed resistance against reverse transcriptase inhibitors. Even more worrying is 
the observation that 62.5% of the patients failing treatment, developed multi-class 
resistance. This will significantly impact future treatment options, especially because 
only few drugs for second-line treatment are available in resource-limited settings. 
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Regular viral load measurements can avoid the accumulation of drug resistance and, 
combined with adherence counselling, they can increase the chance to remain on a 
first-line regimen for a longer period. 
 
Global efforts to provide universal access to ART should continue, despite the limited 
possibility to adequately monitor patients on treatment in low and middle-income 
settings. Yet, the need for affordable and accurate viral load and resistance assays 
should be emphasized. Researchers and commercial companies should continue 
their search for low-cost laboratory assays to monitor HIV-1 patients on treatment 
and more generic ARV drugs should be made available in resource-limited settings in 
order to improve the worldwide HIV care. 
Samenvatting 
Samenvatting 
Ondanks wereldwijde inspanningen voor de preventie van HIV infectie en het 
verbeteren van de beschikbaarheid van antiretrovirale therapie (ART), blijft HIV/AIDS 
de belangrijkste infectieuze doodsoorzaak ter wereld. Eind 2007 werden al meer dan 
33 miljoen mensen getroffen door HIV/AIDS, waaronder 2.5 miljoen nieuwe infecties. 
Sub-Saharisch Afrika blijft het meest getroffen gebied. Alhoewel het gebruik van ART 
de HIV gerelateerde mortaliteit enorm heeft doen dalen in de geïndustrialiseerde 
wereld, hebben wereldwijd slechts 28% van de mensen die therapie nodig hebben, 
ook toegang tot de medicatie. Ondertussen werden er wereldwijde initiatieven 
opgezet om ART universeel toegankelijk te maken tegen 2010. De uitbreiding van 
wereldwijde beschikbaarheid van ART moet een prioriteit blijven, maar de testen die 
nodig zijn om de respons op de behandeling te meten zijn minstens even belangrijk. 
Het meten van de virale lading en het opsporen van resistentie zijn standaard testen 
in ontwikkelde landen. Het gebruik van deze testen in ontwikkelingslanden blijft 
echter beperkt door de hoge kost en het gebrek aan goed uitgeruste laboratoria. 
Daarom is er een hoge nood om eenvoudige en betaalbare alternatieven voor de 
huidige virale lading en resistentietesten te ontwikkelen en te valideren, die dan 
geïmplementeerd kunnen worden in ontwikkelingslanden. 
 
Het regelmatig meten van de virale lading is een belangrijke parameter om vroeg 
therapiefalen op te sporen. Hierdoor kan de accumulatie van mutaties die tot 
resistentie leiden, vermeden worden. Het meten van de virale lading is ook bruikbaar 
voor het diagnosticeren van perinatale infecties en als parameter voor therapietrouw 
kunnen ze onnodige therapie wijzigingen voorkomen. Bovendien kunnen deze testen 
gebruikt worden om de efficiëntie van ART programma’s te evalueren. De WHO 
erkent de nood voor deze testen en pleit voor het gebruik van eenvoudige, goedkope 
en accurate testen voor het meten van de HIV virale lading. Er werden reeds drie 
types van alternatieve testen voorgesteld: testen om p24 Ag te bepalen, testen die 
de activiteit van het reverse transcriptase meten en ‘in-house’ real-time PCR testen. 
De laatste twee geven de meest belovende resultaten, maar over de bruikbaarheid 
ervan in ontwikkelingslanden is nog niet veel geweten. Daarom besloten we om het 
nut van de ExavirLoad (Cavidi) en de Generische HIV virale lading (Biocentric) te 
evalueren in Mombasa, Kenia. Onze studie toonde aan dat beide testen goed 
correleerden met de Amplicor HIV-1 Monitor v1.5 (Roche), maar dat de specificiteit 
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inferieur was aan deze laatste, vooral in het geval van de ExavirLoad. Beide testen 
kunnen echter waardevol zijn voor het bepalen van virale ladingen, maar hebben elk 
hun nadelen en daarom moet de keuze voor de juiste test in iedere setting apart 
gemaakt worden, rekening houdend met de specifieke voor- en nadelen. 
 
De accumulatie van verschillende met resistentie geassocieerde mutaties, met vaak 
kruisresistentie tegen verschillende producten tot gevolg, is niet enkel een probleem 
voor de individuele patiënt, maar verhoogt ook het risico op overdracht van resistent 
virus en dus de verspreiding van resistentie in de populatie. Er is bijgevolg nood aan 
betaalbare genotypische resistentietesten. De hoge gevoeligheid van onze ‘in-house’ 
genotypische test laat de gecombineerde detectie van plasma HIV-1 en opsporing 
van resistentiemutaties toe. 
Het wijdverspreide gebruik van testen voor virale lading en genotypering in 
ontwikkelingslanden is niet enkel gelimiteerd door de hoge kostprijs, maar ook door 
het gebrek aan infrastructuur. Eén van de uitdagingen is het garanderen van een 
koude keten die nodig is voor het bewaren en transporteren van bloedstalen. In dit 
opzicht hebben we de ‘in-house’ test voor resistentiebepaling aangepast voor gebruik 
van cellulair DNA uit vol bloed en droge bloed spots (DBS). We konden aantonen dat 
het extraheren en vervolgens sequeneren van HIV DNA uit vol bloed en DBS 
mogelijk is. De resultaten bekomen via DNA sequenering zijn bruikbaar voor 
epidemiologische studies, zoals het analyseren van de HIV subtype-verspreiding en 
van de algemene verspreiding van resistentiemutaties. We konden echter ook 
aantonen dat bij het opvolgen van individuele patiënten, het sequeneren van RNA 
veel meer informatie geeft dan het sequeneren van DNA, vooral bij vroeg 
therapiefalen. 
 
Ondanks het gebrek aan goede laboratoriumtesten om behandelde patiënten op te 
volgen, zijn de inspanningen om ART meer toegankelijk te maken voor HIV-patiënten 
in ontwikkelingslanden niet zonder resultaat. In Mombasa vonden we dat 86.2% van 
de patiënten, die voor minstens 6 maanden behandeld werden, een niet 
detecteerbare virale lading bereikten. Nochtans is het aantal falende patiënten met 
resistentie zorgwekkend. In onze studie ontwikkelden 87.5% van de patiënten met 
een detecteerbare virale lading resistentie tegen reverse transcriptase inhibitoren. 
Het feit dat 62.5% van de falende patiënten resistentie ontwikkelden tegen meerdere 
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klassen van geneesmiddelen is nog meer verontrustend. Dit zal een belangrijke 
invloed hebben op toekomstige therapie mogelijkheden, vooral omdat er in 
ontwikkelingslanden slechts een beperkt aantal geneesmiddelen beschikbaar zijn 
voor tweedelijns therapie. Regelmatige metingen van de virale lading kunnen de 
accumulatie van resistentie beperken en kunnen, in combinatie met verbeterde 
therapietrouw, de kans om de patiënten langer op een eerstelijns therapie te houden, 
verhogen. 
 
Ondanks de beperkte mogelijkheden om patiënten op therapie op te volgen in 
ontwikkelingslanden, moeten we de universele beschikbaarheid van ART blijven 
promoten. Anderzijds blijft de nood aan betaalbare virale lading en resistentietesten 
enorm hoog. Onderzoekers en commerciële firma’s moeten blijven volharden in hun 
zoektocht naar goedkope laboratoriumtesten om HIV geïnfecteerde patiënten op 
therapie op te volgen. Bovendien moeten meer generische geneesmiddelen 
beschikbaar gemaakt worden in ontwikkelingslanden om de zorg voor HIV 
geïnfecteerden wereldwijd verder te verbeteren. 
Résumé 
Résumé 
Malgré des efforts importants de prévention et pour améliorer l’accès au traitement, 
le VIH et le SIDA demeurent la principale cause de mortalité par maladie infectieuse. 
Fin 2007, environ 33 millions de personnes vivaient avec le VIH ou le SIDA; chaque 
année, environ 2.5 millions de personnes sont nouvellement infectées, l’Afrique 
Subsaharienne étant la région la plus affectée. Dans les pays industrialisés, 
l’utilisation du traitement antirétroviral (TAR) a considérablement réduit la mortalité 
liée au VIH. Mais au niveau mondial, seuls 28% des personnes nécessitant le TAR 
ont dans les faits accès à celui-ci. Différentes initiatives visant à un accès universel 
au TAR d’ici à 2010 sont en cours au niveau mondial. L’élargissement de l’accès au 
TAR au niveau mondial doit rester une priorité. Cependant, il est tout aussi important 
de disposer d’outils permettant d’évaluer la réponse au traitement. Dans les pays 
industrialisés, différents tests permettant de mesurer la charge virale et d’identifier 
les mutations entraînant des résistances aux médicaments font maintenant partie de 
la prise en charge standard. Dans les situations de ressources limitées, l’utilisation à 
grande échelle de ce type de tests est cependant limitée par leur prix élevé et parce 
qu’ils ne peuvent être utilisés que dans des laboratoires bien équipés. Il y a donc un 
besoin urgent de développer et d’évaluer des méthodes alternatives de mesure de la 
charge virale et de détection des résistances qui soient simples et bon marché et 
puissent être mises en œuvre dans les situations de ressources limitées. 
 
La mesure régulière de la charge virale est un paramètre important pour détecter de 
façon précoce un échec thérapeutique, permettant de ce fait d’éviter la multiplication 
des mutations à l’origine de résistance, et, en cas de montée de la charge virale, 
d’insister à nouveau sur le conseil en matière d’observance du traitement, prévenant 
ainsi des changements de traitement. Cette mesure permet aussi de poser le 
diagnostic d’infection périnatale. Les tests de charge virale peuvent également être 
des outils utiles pour la surveillance sentinelle dans les programmes de TAR. L’OMS 
reconnaît qu’il y a un besoin de tests de charge virale, et encourage pour la mesure 
de la charge virale l’utilisation d’outils simples, peu coûteux et précis. Trois 
différentes alternatives de tests ont été proposées: les tests de quantification de l’Ag 
p24, les tests de mesure de l’activité de la transcriptase inverse, et les tests de PCR 
en temps réel de fabrication interne. Ces deux dernières alternatives de test ont 
donné des résultats très encourageants. On ne dispose cependant que de peu 
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d’information sur les performances de ces tests en situation de ressources limitées. 
Nous avons donc décidé d’évaluer l’utilité d’ExavirLoad (Cavidi) et de Generic HIV 
viral load (Biocentric) en situation de vie réelle à Mombasa, Kenya. Nous avons 
retrouvé une bonne corrélation de ces deux tests en les comparant au test Amplicor 
HIV-1 Monitor v1.5 (Roche). La spécificité était cependant moins bonne, notamment 
pour le test ExavirLoad. Ces deux tests pourraient être des outils précieux pour la 
mesure de la charge virale. Ils ont pourtant certains inconvénients. Le choix du test 
pour mesurer la charge virale devrait donc être fait individuellement pour chaque site, 
en prenant en compte les avantages ou les inconvénients de chacun de ces tests. 
 
Ne pas disposer de la charge virale (par manque de méthodes abordables pour la 
mesurer) comme paramètre pour évaluer de façon précoce l’échec thérapeutique 
augmentera le risque d’accumuler des mutations entraînant des résistances, 
entraînant de ce fait un haut risque de résistances croisées. Ceci posera non 
seulement un problème individuel au niveau du patient, mais augmentera aussi le 
risque de transmission de virus hautement résistants dans la population, ce qui peut 
compromettre les futures options de traitement. Il est donc urgent de pouvoir 
disposer de tests de résistance génotypique abordables; un test génotypique de 
fabrication interne a donc été évalué. Ce test présente une sensibilité élevée, ce qui 
permet à la fois la détection du VIH-1 dans le plasma et celle d’éventuelles mutations 
entraînant des résistances aux médicaments; on aurait alors moins besoin de tests 
standard de mesure de la charge virale et de tests génotypiques. Leur coût élevé, 
mais aussi le manque d’infrastructures suffisantes, limite l’utilisation à grande échelle 
des tests de charge virale et du génotypage dans les situations de ressources 
limitées. L’un des défis posés est la nécessité de garantir la chaîne du froid 
nécessaire lors du stockage et du transport des échantillons de sang. Notre test de 
fabrication interne de génotypage a été adapté pour l’utilisation d’ADN cellulaire 
provenant de sang complet ou de gouttes de sang séchées. Notre étude a montré 
qu’il est possible puis de séquencer l’ADN du VIH-1 provenant de sang complet ou 
de gouttes de sang séchées. Le séquençage d’ADN peut être utile pour des études 
épidémiologiques, comme l’analyse de la distribution des sous-types et de la 
distribution des mutations entraînant des résistances aux médicaments. Notre étude 
confirme que le séquençage de l’ARN demeure supérieur à celui de l’ADN pour le 
suivi individuel des patients, notamment en cas d’échec thérapeutique. 
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Même s’il l’on manque de tests biologiques adéquates pour faire le suivi des patients 
sous traitement, il est maintenant démontré qu’il est possible d’élargir l’accès au TAR 
dans les pays à revenus faibles ou modérés. Dans les Centre de traitement global 
(Comprehensive Care Centre) à Mombasa, nous avons ainsi retrouvé un taux de 
succès thérapeutique de 86.2% chez les patients traités au cours des 6 derniers 
mois. Parmi les patients en échec thérapeutique, le taux d’accumulation de 
résistance entraînant des mutations demeure un problème. Dans notre étude, 87.5% 
des patients présentant une charge virale détectable présentaient une résistance aux 
inhibiteurs de la transcriptase inverse. Nous avons également observé que 62.5% 
des patients en échec thérapeutique présentaient une résistance de type multi-
classe, ce qui est encore plus préoccupant. Ceci aura un impact important sur les 
futures options de traitement, notamment du fait que l’on ne dispose que de 
quelques médicaments de deuxième intention dans les situations de ressources 
limitées. Une mesure régulière de la charge virale peut permettre d’éviter 
l’accumulation de résistances. Combinée à un conseil en matière d’observance du 
traitement, elle peut aider à ce que les patients aient plus de chances de demeurer 
sous un traitement de première intention. 
 
Il est nécessaire de poursuivre les efforts au niveau mondial pour permettre un accès 
universel au TAR, malgré les possibilités limitées d’offrir un suivi adéquat aux 
patients le recevant dans les situations de revenu modérés ou limités. Il faut 
cependant insister sur le fait que l’on a un grand besoin de tests de mesure de la 
charge virale et de détection de résistances qui soient abordables et précis. Les 
chercheurs et les firmes doivent continuer leurs recherches pour des tests bon 
marché permettant le suivi des patients infectés avec le VIH-1 sous traitement. Afin 
d’améliorer la prise en charge au niveau mondial, des médicaments antirétroviraux 
génériques doivent être mis à la disposition dans les situations à ressources limitées.  
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Ukimwi bado ndiyo maambukizi yanayoongoza katika kusababisha vifo licha ya 
jitihada za ulimwengu mzima za kukinga maambukizo hayo na kupatikana kwa 
huduma nzuri za matibabu. Kufikia mwisho wa mwaka wa 2007, takribani watu 
milioni 33 walikuwa wanaishi na virusi na kuugua ukimwi, huku wengine milioni 2.5 
wakipata maambukizo mapya kila mwaka na eneo la kusini mwa Sahara ya Africa 
likiathirika zaidi. Ijapokuwa matumizi ya madawa yanayopunguza makali ya virusi 
(ART) yamechangia sana kwa kupunguza idadi ya vifo vinavyotokana na ukimwi 
katika nchi zilizo na ustawi wa viwanda, ni asilimia 28 tu ya watu wanaohitaji ART 
ulimwenguni wanazipata. Mikakati ya kimataifa inayolenga kupatikaniwa ART kwa 
wote wanaozihitaji kufikia mwaka wa 2010 bado inaendelea. Upanuzi wa kupatikana 
kwa ART kwa wote ulimwenguni ni lazima ubaki kama jambo linalotiliwa maanani 
sana, huku vifaa vinavyotumiwa kukadiria ufanisi wa matibabu vikiwa na umuhimu 
sawa. Vipimo vya kupimia wingi wa virusi katika damu na kutambua virusi sugu kwa 
matibabu vimekuwa ndiyo kiwango cha kadri cha utunzaji katika ulimwengu uliyo na 
ustawi wa viwanda. Hata hivyo matumizi mengi ya hivi vipimo katika sehemu zenye 
uhaba wa bidhaa bado yanakabiliwa na bei za juu za vipimo na mahitaji ya 
mahabara zilizo na vifaa kikamilifu. Kwa hivyo kuna dharura ya kuboresha na 
kuzijaribu njia rahisi na ambazo watu wanaweza kumudu za kupimia wingi wa virusi 
na kutambua virusi sugu, ambazo zinaweza kutumika katika sehemu zenye 
upungufu wa vifaa. 
 
Upimaji wa mara kwa mara wa wingi wa virusi ni hatua muhimu ili kutambua 
mapema kushindwa kwa matibabu, ili kuepukana na urundikaji wa virusi sugu kwa 
matibabu. Wanaweza pia kupima maambukizo wakati wa kuzaa ili kuepusha 
mabadiliko ya matibabu yasiyostahili, kwa kufuatilizia uendelezaji wa matumizi ya 
ART. Zaidi ya hayo, vipimo vya wingi wa virusi vinaweza kuwa vyenye manufaa 
kama vifaa vya kuthamini ubora wa mpango wa ART. Shirika la afya duniani 
linatambua haja ya vipimo vya wingi wa virusi na linahimiza matumizi ya vifaa vya 
kawaida, visivyo ghali na vinavyoaminika kwa kupima wingi wa virusi vya ukimwi-1. 
Aina tatu za vipimo vingine vinavyoweza kutumika vimependekezwa: Vipimo 
vinavyoweza kujumuisha p24 Ag, vipimo vya kupima transcriptase activity na in-
house real-time PCR. Hivi viwili vya mwisho vilionyesha majibu yenye matumaini 
zaidi, hata hivyo maelezo machache tu juu ya jinsi hivi vipimo vinavyofanya kazi 
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katika sehemu zilizo na upungufu wa bidhaa yanapatikana. Kwa hivyo tumeamua 
kuangalia umuhimu wa ExavirLoad (Cavidi) na Generic HIV viral load (Biocentric) 
katika hali halisi ya maisha hapa Mombasa, Kenya. Tulipata uhusiano mzuri kwa 
vipimo vyote viwili vikilinganishwa na kipimo cha Amplicator HIV-1 Monitor v1.5 
(Roche), lakini umaalumu ulikuwa mchache, haswa kwa Exavirload. Hivi vipimo 
vyote viwili vinaweza kuwa vifaa muhimu vya kupimia wingi wa virusi, hata hivyo vina 
ubaya wake na uchaguzi wa kipimo sawa lazima ufanyike katika kila kituo, 
ukizingatia uzuri na ubaya wa kila kifaa. 
 
Ukosefu wa vipimo vya kupimia wingi wa virusi vya bei nafuu kama hatua ya 
kukadiria kushindwa kwa matibabu kwa mapema, kutaeneza athari za kuongezeka 
kwa virusi sugu kunaosababisha uwezekano wa juu wa cross-resistance. Hii 
haitaleta tu matatizo kwa mgonjwa huyu binafsi, lakini pia itaongeza athari za 
kusambaza virusi ambavyo ni sugu sana kwa jamii, ambapo itakuwa inakatiza njia za 
baadaye za matibabu. Kuna mahitaji ya haraka ya kuwa na vipimo vya bei nafuu vya 
kupimia usugu na kwa hivyo kipimo cha in-house genotyping kilijaribiwa. Kwa sababu 
ya ubora wa kifaa hiki, kinachoruhusu muungano wa utambuzi wa virusi vya ukimwi-
1 kwenye damu na uwezekano wa virusi ambavyo huenda vikawa sugu kwa 
matibabu, kumekuwa na kupungua kwa mahitaji ya kiwango cha kadri cha vipimo 
vya wingi wa virusi na aina ya virusi. Matumizi mengi ya kupima wingi wa virusi na 
aina ya virusi katika sehemu zilizo na upungufu wa bidhaa, hairudishwi nyuma tu na 
gharama za juu za hivi vipimo lakini pia na ukosefu wa mtandao mzuri wa barabara. 
Changamoto mojawapo ni kuhakikisha ubaridi, haja ya kukusanya na kusafirisha 
sampuli za damu. Kwa sababu hiki kipimo chetu cha in-house genotyping 
kilikubaliwa kwa matumizi ya cellular DNA kutoka kwa damu nzima na matone ya 
damu yaliyokauka (DBS).  
Utafiti wetu ulionyesha uwezekano wa kuzitenganisha kasha kupangilia DNA ya 
virusi vya ukimwi-1 kutoka kwa damu nzima na DBS. Ijapokuwampangilio wa DNA 
unaweza kusaidia katika masomo ya afya za jamii, kwa kukagua aina tofauti tofauti 
za virusi vya ukimwi zinavyopatikana katika jamii na usambazaji wa virusi sugu kwa 
matibabu, utafiti wetu ulionyesha kwamba mpangilio wa RNA bado ni bora kuliko 
mpangilio wa DNA katika kumfuatilizia mgonjwa mmoja mmoja, haswa mwanzoni 
mwa kushindwa kwa matibabu. 
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Kuongeza ueneaji wa ART katika nchi za chini na zile za kiwango cha kadri cha 
mapato imeonyosha kuwa ya mafanikio, mbali na upungufu wa vipimo vya mahabara 
vya kuangalia hali za wagonjwa walioko kwenye matibabu. Pia, tuliona mafanikio ya 
matibabu ya asilimia 86.2 kwa wale waliotibiwa kwa muda usiopungua miezi 6 katika 
kituo cha utunzaji wa kina (comprehensive care center) cha Mombasa. Hata hivyo 
kiwango cha ulumbikizaji wa virusi sugu miongoni mwa wagonjwa ambao matibabu 
hushinda ni jambo la kutia shaka. Katika utafiti wetu, asilimia 87.5 ya wagonjwa walio 
na kiwango cha virusi kinachoweza kutambulika, walipata usugu dhidi ya 
transcriptase inhibitors. Kinachotia shaka zaidi ni kwamba asilimia 62.5 ya wagonjwa 
walioshindwa na matibabu, walijenga usugu dhidi ya baadhi ya madawa. Hii itakuwa 
na athari kubwa katika mipango ya baadaye ya matibabu, haswa kwa sababu ni 
madawa machache tu ya matibabu ya mkondo wa pili yanapatikana katika sehemu 
zenye uhaba wa bidhaa. Upimaji wa mara kwa mara wa kiwango cha virusi unaweza 
kuepusha ulumbikizaji wa virusi vilivyo sugu kwa matibabu, na kukiwemo ushauri wa 
kuendeleza matumizi ya dawa, yanaweza kuongeza uwezekano wa kubaki katika 
kiwango cha kwanza cha matibabu kwa muda mrefu. 
 
Juhudi za ulimwengu za kufanya ART zifikiwe na watu wote lazima ziendelee, mbali 
na kuwepo kwa uwezekano mdogo wa kuwaangalia wagonjwa walio katika matibabu 
kwenye sehemu za mapato ya chini na ya kadri. Hata hivyo, haja ya kuwa na vipimo 
vya kiwango cha virusi na usugu kwa bei nafuu na vinavyo aminika ni lazima kutiliwe 
maanani. Watafiti na kampuni za biashara ni lazima waendelee kutafiti vipimo vya 
mahabara vyenye bei nafuu ili kuwafuatilizia wagonjwa wa virusi vya ukimwi-1 walio 
kwenye matibabu na madawa zaidi ya ARV (generic) pia yawe yanaweza kupatikana 
katika sehemu zenye mapato ya chini ili kuboresha utunzaji wa walio na virusi vya 
ukimwi ulimwenguni. 
 xviii 
Introduction and research objectives 
Chapter I: Introduction and research objectives 
1.1. History of Human Immunodeficiency Virus (HIV) 
Promising progress has been made in recent years to tackle the HIV/AIDS (Human 
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) epidemic. This has 
included increasing access to effective treatment for those already infected, and 
prevention programmes to control the spread of the epidemic. However, the number 
of people living with HIV continues to grow, and it is estimated that currently, about 
33 million people and their families are affected by HIV [1]. 
Symptoms of AIDS were first recognized in 1981, when Gottlieb et al. reported an 
increasing number of cases with Karposi’s Sarcoma (KS) and Pneumocystis Carinii 
Pneumonia (PCP) in New York [2]. It was only in 1983 that HIV was recognized as 
the causing agent of AIDS [3, 4].  
1.2. HIV virology 
1.2.1. HIV structure and genome 
HIV belongs to the group of lentiviruses in the family of Retroviridae, which are 
enveloped, positive-stranded RNA viruses. Following infection with the virus, the 
RNA genome is transcribed into double-stranded DNA with the viral enzyme reverse 
transcriptase. The produced double-stranded DNA is subsequently integrated into 
the host genome [5, 6].  
 
Figure 1: HIV virion structure 
Adapted from : www3.niaid.nih.gov 
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HIV virions are spherically shaped with a diameter of 110 nm and consist of a lipid 
bilayer membrane or envelope, surrounding a cone-shaped nucleocapsid (figure 1).  
The envelope is derived from the host cell plasma membrane and is dotted with 
approximately 72 spikes. Each spike is composed of surface units (gp120, SU) that 
are non-covalently linked with the transmembrane units (gp41, TM). The inner 
surface of the lipid bilayer is lined with matrix proteins (MA). The capsid protein p24 
forms the nucleocapsid (NC) that packs the two single stranded RNA copies with the 
reverse transcriptase (RT) molecules. Other viral enzymes, protease (PR) and 
integrase (IN) and some accessory and regulatory proteins (p6, Nef, Vif and Vpr) are 
also found in the nucleocapsid [5, 7].  
 
 
Figure 2: Genomic structure of the human immunodeficiency virus 
Adapted from: http://student.ccbcmd.edu/courses/bio141/lecguide/unit3/viruses/hivgenes.html 
 
An HIV-virion contains two identical copies of positive, single stranded RNA of about 
9.2 kb long. The HIV-1 genome contains nine open reading frames (ORFs). Three of 
these ORFs encode for the Gag, Pol and Env precursor polyproteins which are 
subsequently proteolysed into individual proteins (figure 2). The Gag gene encodes 
for the precursor of the matrix proteins (MA, p17), the capsid protein (CA, p24), the 
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nucleocapsid protein (NC, p7) and p6. The genes for the viral enzymes: protease 
(PR, p10), reverse transcriptase and RNaseH (RT, p66/51) and integrase (IN, p32) 
are found in the Pol region. The Env gene encodes for the precursor for the envelope 
glycoproteins gp120 (SU) and gp41 (TM). The HIV genome also encodes for two 
regulatory peptides (Tat and Rev) and four accessory peptides: vif, vpr, vpu and nef. 
HIV has two genomic forms, single stranded RNA in the extracellular phase of the 
viral replication, and double stranded DNA, integrated as provirus in the host 
genome. In the proviral genome, the ORFs are flanked by two long terminal repeat 
(LTR) regions, which are essential for integration and contain promoters for the 
transcription of the viral genes [6, 8].  
 
1.2.2. Replication cycle 
The HIV-replication cycle can be subdivided in a number of steps (figure 3). The 
infection of a target cell by the virion is initiated by an interaction between the extra-
cellular domain of the viral envelope glycoprotein (gp120) and the CD4 receptor 
located on the plasma membrane of T-lymphocytes and macrophages. This process 
needs additional interaction with the CCR5 or CXCR4 chemokine co-receptors, 
located on the cell surface (step 1). Subsequently, the transmembrane (TM) units 
undergo a conformational change which leads to the fusion of the viral lipid bilayer 
and the host cell plasma membrane whereby the viral core penetrates the cell (step 
2). The virion core is then uncoated to expose the viral nucleoprotein complex 
consisting of MA, RT, IN, Vpr and RNA (step 3). After the viral genome is reverse 
transcribed into a double stranded DNA by viral RT (step 4), the complex is 
transported to the nucleus (step 5). The DNA is then integrated into the host genome, 
a step catalysed by the integrase enzyme (step 6). In the next step, viral transcripts 
are expressed from the promoter in the 5’ LTR while Tat enhances the rate of 
transcription (step 7). The viral Rev protein regulates the processing of the RNA 
transcripts. Most transcripts are double spliced to generate the Tat, Rev and Nef 
proteins (step 8). When sufficient Rev protein is produced, it protects the viral 
transcripts from being spliced and mediates their transport to the cell plasma. In this 
way single spliced and unspliced transcripts are produced (step 9). In step 10 the 
single spliced transcripts are translated into Gag, Gag-Pol and Env precursors. The 
Env precursor is subsequently spliced by a cellular enzyme and gp120 and gp41 
products are transported from the endoplasmic reticulum to the cellular membrane 
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(step 11). The Gag and Gag-Pol polyproteins, the unspliced RNA transcripts and the 
Vif, Vpr and Nef proteins are assembled into a new virion (step 12). This new virion 
starts to bud from the cell membrane, spiked with Env glycoproteins and is 
subsequently released from the cell (step 13). During the maturation step, the Gag 
and Gag-Pol polyproteins are cleaved by the viral protease, assisted by the Vif 
protein. The mature virion is now ready to infect a new cell (step 14) [6-8]. 
 
 
Figure 3: Replication cycle of HIV 
The different steps of the replication cycle are explained in the text. 
Adapted from: Turner and Summers, J Mol Biol, 1999 [7] 
 
4 
Introduction and research objectives 
1.2.3. Immunopathogenesis of HIV infection 
The course of HIV infection differs substantially from individual to individual. The time 
from initial infection until progression to AIDS in typical progressors is eight to ten 
years. However a subset of patients (10 to 15%) progress to AIDS within two to five 
years (rapid progressors), while long-term non-progressors (<5%) remain 
asymptomatic for at least 10 years [9]. 
The clinical course of HIV generally includes three phases or stages: primary 
infection, clinical latency and AIDS. Some HIV-infected patients remain 
asymptomatic during the primary infection phase, though most show symptoms of 
a flue-like syndrome including symptoms like fever, sore throat, skin rash, nausea 
etc. [10]. Virologically, a burst of viremia (up to 107 HIV RNA c/ml of plasma) and a 
high level of infected peripheral blood mononuclear cells (PBMCs) are associated 
with this primary phase of the infection [11-13], while on the immunological level, the 
CD4+ T cells rapidly decrease. The control of virus expression by the immune 
response is not very effective in the period between the acute primary infection and 
the chronic infection. Six to eight weeks after the onset of symptoms, the acute viral 
syndrome resolves and the HIV specific immune responses appear. HIV specific 
cytotoxic T lymphocytes eliminate virus-expressing cells and production of antibodies 
against different HIV proteins may contribute to the down regulation of viremia [11, 
12]. These antibodies form immune complexes, trap the virus in the reticulo-
endothelial system, while neutralizing antibodies are only detected several months 
after seroconversion [14]. The clinical latency phase starts with the down regulation 
of viremia and a temporary rise of CD4+ T lymphocytes. Due to the lack of ability to 
completely regenerate or repopulate the CD4+ T lymphocytes, a persistent decline in 
the immune system is observed, while virus replication is still ongoing at the baseline 
level. When the CD4+ T cell count drops < 200 cells/µl the immune system is no 
longer capable of controlling the virus and other pathogens and the patient becomes 
vulnerable to opportunistic infections. This is the onset of the AIDS [9]. The evolution 
of the HIV infection is depicted in figure 4. 
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Figure 4: The natural evolution of HIV infection 
Adapted from: Fauci et al. Ann Intern Med, 1996 [15] 
1.3. HIV diversity and geographical distribution 
Different factors contribute to the extremely high genetic heterogeneity of HIV. With 
only 2.5 days needed to produce new viruses, the turnover of the virus is short and 
about 1010 virions are produced daily [16, 17]. The viral reverse transcriptase lacks 
proofreading and as a result, a high rate of incorrect nucleotide substitutions occurs 
(10-4/nucleotide or 1 mutation per replication cycle). Moreover a recombination 
process makes the exchange of larger genomic fragments possible [18]. As a result 
the natural polymorphisms in HIV proteins is high [19, 20].  
Based on different reactions in antibody binding assays and on phylogenetic analysis 
of genetic sequences, two types of HIV are recognized: HIV-1 and HIV-2. While HIV-
1 is widely distributed throughout the world, the spread of HIV-2 is mainly limited to 
West-Africa [21]. HIV-2 is further divided in 5 subtypes. Nucleotide sequence 
comparisons allow distinction of 3 groups among HIV-1 isolates. Most HIV-1 isolates 
can be classified as group M viruses, while group O represents some rare outliers. In 
1998, a third group (group N) was proposed to classify HIV-1 isolates that were 
different from group M and O viruses. Within group M, nine subtypes (A-D, F-H, J 
and K) and 32 circulating recombinant forms (CRFs) are recognized [22]. The global 
HIV-1 subtype distribution is shown in figure 5. Subtype C is the most widespread of 
all HIV-1 infections (50%) while subtype A, B, D and G are responsible for 12, 10, 3 
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and 6% of the infections, respectively. Subtypes F, H, J and K together cause only 
0.94% of the infections worldwide. About 10% of the people living with HIV are 
infected with CRF01_AE (5%) or CRF02_AG (5%), the two most important CRFs. 
Other recombinant forms account for 8% of the remaining infections. [23] 
 
 
Figure 5: Regional distribution of HIV-1 subtypes and recombinants 
Adapted from: http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html 
 
When we look at the subtype distribution, we see that subtype C is almost exclusively 
responsible for all infections in Southern Africa, India and Ethiopia, responsible for 
30, 13 and 4% of global infections respectively. In West Africa, which harbours 16% 
of the global HIV-1 infections, subtype A, G and CRF02_AG are the most 
predominant. Subtype A, C, D and unique recombinant forms make up most of the 
HIV-1 infections in East Africa, which has 10% of global infections. Subtype A 
dominates the subtype diversity in Kenya, while subtypes D, C and G are responsible 
for most of the remaining infections [24]. The greatest subtype diversity is detected in 
Central Africa, which contributes to only 5% of patients globally infected with HIV-1 
live. CRF01_AE is responsible for most infections in South and South-East Asia 
(excluding India), while in East Asia the burden of infections is caused by subtype B, 
CRF01_AE and other recombinants. In North Africa and the Middle East subtype C 
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and D predominate. Subtype A and B are responsible for most HIV-1 infections in 
East-Europe and Central Asia and CRF03_AB has only been identified in individuals 
from Eastern European origin. Finally subtype B is the abundant subtype in North 
America, West-Europe, the Caribbean and Latin America. 
 
1.4. Antiretroviral therapy and resistance 
A first breakthrough in antiretroviral therapy (ART) was made in 1987 with the 
approval of zidovudine (AZT) by the US Food and Drug administration (FDA). 
Though the first reports proved efficacy of the drug, it was soon discovered that HIV 
quickly developed drug resistance when AZT monotherapy was given [25, 26]. 
During the next couple of years other RT inhibitors became available, but it was only 
in 1996 that a major breakthrough trial was announced at the 3rd Conference on 
Retroviruses and Opportunistic Infections where Gulick et al. showed the potent 
antiretroviral activity of the triple combination of two RT inhibitors and a protease 
inhibitor [27]. Soon thereafter some publications showed that what is now generally 
accepted as triple therapy, also known as highly active antiretroviral therapy 
(HAART), can suppress viral load to levels below the detection limit of current assays 
and restore the number of CD4+ T cells in peripheral blood close to normal levels [28, 
29]. HAART was quickly introduced in the clinic and had a dramatic impact on the 
mortality and morbidity among HIV-infected patients. By October 2007, 24 
antiretroviral drugs had been approved by the FDA. These can be divided in five 
classes (table 1).  
 
NRTIs NNRTIs PIs 
Fusion and 
Entry Inhibitirs 
Integrase 
Inhibitors 
Abacavir (ABC) Delavirdine (DLV) Amprenavir (APV) Enfuvirtide (ENF) Raltegravir (RAL) 
Didanosine (ddI) Efavirenz (EFV) Atazanavir (ATV) Maraviroc (MVC)  
Emtricitabine Nevirapine (NVP) Darunavir (DRV)   
Lamivudine (3TC)  Fosamprenavir (APV)   
Stavudine (d4T)  Indinavir (IDV)   
Tenofovir (TDF)  Lopinavir (LPV)   
Zalcitabine (ddC)  Nelfinavir (NFV)   
Zidovudine (AZT)  Ritonavir (RTV)   
  Saquinavir (SQV)   
  Tipranavir (TPV)   
Table 1: FDA approved antiretroviral drugs  
Adapted from http://www.fda.gov/oashi/aids/virals.html, October 2007 
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Though it is proven that HIV drug resistance emerges much slower under the 
pressure of a combination therapy, resistance mutations against all drug classes 
have been reported.  
Nucleoside/nucleotide RT inhibitors (NRTIs) compete with the natural dNTPs to 
bind the RT enzyme. Once a NRTI is incorporated in the DNA, it acts as a chain 
terminator because it lacks a 3’ hydroxyl group. Resistance against this class of RT 
inhibitors can arise either by amino acid changes that increase the discrimination 
between natural nucleotides and NRTIs or by promoting the removal of NRTIs [30].  
Unlike NRTIs, non-nucleoside RT inhibitors (NNRTIs) do not need activation by 
intracellular kinases. NNRTIs cause an inactivating conformational change in the RT 
enzyme by binding the hydrophobic pocket. These inhibitors are HIV-1 specific and 
will therefore not bind HIV-2 RT or cellular DNA polymerase. Some mutations in the 
RT gene cause resistance by altering size, shape or polarity of the binding pocket or 
by affecting accessibility of NNRTIs to this site [31, 32]. 
The third class of ARV drugs, the protease inhibitors (PIs), bind to the PR cleavage 
site and inhibit the enzyme using two different mechanisms. They can bind to the 
active site, or mimic the transition state during peptide cleaving. Unfortunately, the 
hypothesis that the PR gene does not mutate as readily as RT gene has not been 
proven. On the contrary, polymorphisms have been found at more than half of the 
amino acids of PR. Additionally, more than 20 PR mutations are associated with 
reduced susceptibility to PI treatment. Major PI mutations can cause a 
conformational change by a single point mutation, thereby improving the selection of 
natural substrates for the protease enzyme. A number of minor mutations, in 
combination with a primary mutation, result in high level resistance due to the 
compensation for the loss of viral fitness of a mutated virus by the secondary 
mutations. Moreover, some mutations in the gag gene can adapt the gag cleavage 
site or improve the incorporation of PR in the virion in order to optimize the cleavage 
activity of a mutated PR enzyme [33, 34]. 
Lately 3 new drug classes have been added to the list of FDA approved ARV drugs. 
Fusion and entry inhibitors work by preventing the virus from infecting a cell, by 
either inhibiting fusion between the virus and the host cell or by blocking the co-
receptors. Only one fusion inhibitor (ENF) was has been approved by the FDA. It is 
the binding of gp120 to the cellular receptor CD4 and a chemokine co-receptor, 
triggering a series of complex conformational changes in gp41 that leads to the 
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fusion of viral and cellular membranes. ENF inhibits this fusion by preventing gp41 to 
undergo a fusogenic conformation. Unfortunately, HIV can again reduce potency of 
this drug by the selection of resistance mutations. Recently, the first co-receptor 
blocker, Maraviroc, was approved by the FDA. This drug makes the CCR5 receptor 
unavailable for ‘R5 tropic’ HIV, whereby the virus cannot engage with the CD4+ T-cell 
to initiate an infection. The last new class of antiretroviral drugs that has received a 
lot of attention lately are the integrase inhibitors. Raltegravir, which was approved 
by FDA in October 2007, prevents the integration of the viral genome into the host 
cell DNA.  
 
1.5. Clinical assessments and laboratory tests in HIV-infected patients 
After an HIV-infection has been confirmed by an HIV antibody test, clinical staging is 
part of the baseline assessment on entry into care and treatment programs. 
Additionally two surrogate laboratory markers, the number of CD4+ T cells in the 
blood and the concentration of HIV RNA in the plasma (viral load), are routinely used 
to determine disease progression, the need for treatment and the efficacy of drug 
regimens.  
 
1.5.1. Clinical staging 
The WHO HIV clinical staging system [35] remains an essential and cheap tool to 
assess the disease status at baseline, to guide the decision to start ART and to 
follow-up patients on treatment. The disease progression is divided into four stages. 
The first one is the asymptomatic stage. Patients with mild clinical symptoms like 
herpes zoster infection, recurrent oral ulcerations, chronic upper respiratory tract 
infections among others, are classified as being in clinical stage 2. In clinical stage 3 
symptoms become more advanced and chronic diarrhoea, unexplained persistent 
fever, TB and chronic lung disease etc. can appear. Finally, the occurrence of 
Kaposi’s Sarcoma, pneumocystis pneumonia, severe wasting, chronic herpes 
simplex infections etc. point to the manifestation of the AIDS or clinical stage 4 (table 
2). This staging system is quite sensitive in predicting disease progression and 
treatment failure when combined with an immunological staging or even viral load 
assays, when available. 
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WHO Clinical stage HIV associated symptoms 
Immune Status 
(CD4+ T cells/µl) 
1 no symptoms >500 
2 mild symptoms 350-499 
3 advanced symptoms 200-349 
4 severe symptoms <200 
 
Table 2: WHO Clinical staging 
 
1.5.2. CD4+ T cell testing 
The European [36, 37] and US guidelines [38] recommend a baseline CD4+ T cell 
count and a viral load test at the first visit, after HIV infection has been confirmed by 
an antibody test. The CD4+ T cell count serves as a clinical indicator of the 
immunocompetence of the HIV-infected individual. The number of CD4+ T cells is the 
most important consideration in the decision of ART initiation. In the developed world 
it is generally recommended to start treatment as soon as the CD4+ T cells drop 
below 350 cells/µl [36-38], while WHO recommends to start treatment in resource-
limited settings before the CD4+ T cells drop below 200 cells/µl [39]. An increase in 
CD4+ T cells of 100 cells/µl per year is an indication of adequate viral suppression on 
treatment [40]. Ideally, the CD4+ T cell count should be performed at least every 3 to 
6 months.  
 
1.5.3. Viral load testing 
Plasma HIV RNA viral load is a critical parameter for evaluating response to ART. 
The goal of ART is to suppress the viral replication to a level that viral RNA is no 
longer detectable in the plasma. Effective regimens and good adherence should 
result in a viral load decrease of at least 1 log10 c/ml per month and the achievement 
of an undetectable viral RNA level (< 50 c/ml) within 16 to 24 weeks [41]. It is 
therefore recommended that the viral load should be monitored closely after 
treatment initiation until full viral suppression is obtained [36-38]. Once viral load 
suppression has been obtained, guidelines recommend a regular viral load follow-up 
every 3 to 6 months to confirm that the virus remains suppressed [42, 43]. A 
confirmed rebound in plasma viral load may indicate a poor adherence, the 
development of drug resistance hence virological failure, or both [44].  
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The inability to detect virological failure, due to unavailability of viral load assays as is 
often the case in resource-limited settings, may lead to an accumulation of resistant 
mutations and the selection of viruses with broad cross-resistance to antiretrovirals. 
This might jeopardize future treatment options for the individual patients and for 
recently infected patients who could be infected with a circulating resistant virus. 
1.5.4. Resistance testing 
When clinical, immunological or virological parameters indicate that a specific 
regimen does not have the desired effect of viral suppression, a resistance test can 
provide information about the presence of resistance mutations. This information can 
help the clinician to choose the most appropriate new regimen. The limited 
experience with mono- and bi-therapy in resource-limited settings might restrict the 
prevalence of resistant virus in these regions compared to Europe and the US where 
broad scale use of suboptimal NRTI regimens was standard practice before the 
introduction of the first PI in 1996. However, the development of resistance is 
inevitable. When a first-line regimen is failing, resistance testing is not strictly 
necessary if all drugs in the regimen can be replaced by drugs without possible 
cross-resistance with the drugs in the failing regimen. Ideally drugs from a different 
class are chosen. Resistance testing in developing countries however might be 
indicative from the first failure onwards because alternatives for a second-line 
treatment are limited and drugs from a different class are not always available. 
Resistance test guidance of this second regimen can improve the efficiency. 
Resistance testing becomes more useful when a second-line regimen is failing 
because it is more difficult to find drugs without possible cross-resistance. A salvage 
or third-line regimen cannot be chosen without information about the specific 
resistance mutations in the patients’ virus.  
Moreover, resistance testing can be a useful tool to prevent unnecessary treatment 
switches in patients with an extremely low adherence. In these patients we might find 
virological failure while there is no evidence for resistance due to the low intake of 
ARVs. In this situation a switch to an expensive second-line regimen can be 
prevented by focusing on the improvement of the patient’s adherence [45, 46]. 
Resistance testing may also be valuable in selecting the initial treatment regimen in 
regions were transmitted drug resistance (TDR) is an increasing concern. The 
prevalence of TDR is significant in countries with established ART programs. Though 
it is difficult to compare data from different studies, the highest prevalence of TDR is 
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seen in the US and Western Europe (6.0% to 24.1%) and some parts of South-
America (3.1% to 22.2%). Since ART became more readily available in resource-
limited settings, a low TDR prevalence has also been detected in some Sub-Saharan 
countries [47]. These regions are even more at risk because therapy switches are 
often based on clinical criteria allowing a prolonged virus replication under drug 
pressure and thereby promoting the development of drug resistant strains. However, 
an excellent virological and immunological response is seen in TDR patients when 
the first-line regimen was based on the baseline resistance results [48, 49]. 
Resistance testing is not only useful before initiation of treatment at an individual 
patient level, it can also be used in population based studies to monitor the success 
of treatment initiatives and the effectiveness of HIV transmission prevention 
programs among HAART treated patients [50]. 
 
1.5.4.1. Phenotypic resistance testing 
Phenotypic assays measure the susceptibility of the virus to the drug directly in an in 
vitro culture assay. This was done initially by enzyme-based assays [51, 52], but 
because of the high cost and the labour-intensity of the procedure a new, replication-
based assay, was developed. The PCR-amplified gene of interest is incorporated in a 
HIV backbone or vector [53-56]. In these assays the susceptibility of the viruses to 
antiretroviral drugs can be measured by the fold difference in drug concentration that 
is needed to inhibit the vector containing the patient sample compared to the wild-
type vector. Results are expressed as fold change in IC50 whereby the IC50 is the 
drug concentration needed to inhibit 50% of the virus replication.  
Even though the interpretation of phenotypic tests might seem less complicated, 
because the susceptibility of the virus is directly measured, an expert opinion is still 
needed as ‘clinical cut-offs’ are scarcely available. Clinical cut-off values are based 
on clinical observations from various drug resistant patients in clinical trials and 
cohorts. At the moment clinicians usually receive two cut-off values: the lower cut-off 
value that gives an idea of when the susceptibility begins to decline, but the drug still 
has partial activity; and the upper cut-off value that is the fold change at which the 
drug completely looses all activity. Because clinical cut-offs are only available for a 
limited number of drugs, the clinician depends on ‘biological cut-offs’ that are derived 
from in vitro susceptibility experiments with clinical isolates from drug naïve patients. 
These values cannot directly link in vitro resistance information with the actual 
phenotype of the virus [57]. 
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1.5.4.2. Genotypic resistance testing 
A genotypic resistance assay determines mutations in PR, RT and gp41 at amino 
acid positions that are known to be related with a decreased susceptibility to 
antiretroviral drugs. A list of detected mutations is generated and frequently updated 
[58]. Mutations are represented by a code, e.g. K103N, whereby the number refers to 
the amino acid position in the respective genes, the first letter is the amino acid 
present in the wildtype and the letter at the end is the mutated amino acid.  
Genotypic assays are the most commonly used methods of testing drug resistance 
because of their relatively low cost (at least in the industrialized world) and low turn-
around time. Nevertheless, these assays have the disadvantage of just producing a 
list of mutations. A correlation between a single mutation and resistance towards a 
specific drug is not always straightforward. Characteristics such as hyper-
susceptibility, cross-resistance and resensitisation are difficult to take into account 
when interpreting the results of genotypic assays [59]. Different algorithms for the 
interpretation of mutational patterns have been developed [60]. Most commonly used 
are the Agence National de Recherche sur le SIDA (ANRS) algorithm [61, 62], the 
Rega Institute (Rega) algorithm [63] and the HIV RT and Protease Sequence 
Database (HIVDB) algorithm (http://hivdb.stanford.edu/index.html). The first two 
algorithms are based on a set of rules that describe specific mutational patterns, 
whereas the HIVDB gives a score to each of the observed mutations. The last 
approach allows taking of unique or complex patterns of mutations into account. 
Mutation scores are based on published literature linking mutations with specific 
antiretroviral drugs and include correlations between the genotype and treatment 
history, genotype and phenotype, and genotype and clinical outcome. Mutations 
known to contribute to hyper-susceptibility are given a negative score. Based on the 
final sum of scores, the virus is said to be susceptible, potential low-level resistant, 
low-level resistant, intermediate resistant or high level resistant. Due to the different 
rules used in the various systems, results from the available algorithms to interpret 
the drug related mutations are not always concordant [64].  
 
Currently two major techniques are used to detect drug resistance related mutations: 
sequencing assays and single point mutation assays. Dideoxynucleotide 
sequencing is a viral population-based sequencing method that determines the 
genetic code of the PCR-amplified target gene, based on the incorporation of 
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fluorescently labelled dideoxynucleotides. This method is most commonly used 
because it has no limitations on the number of mutations that can be detected. 
However, it is less sensitive for minor variants, as each variant should present at 
least 25% of the virus population to become detectable [65]. Several sequencing 
methods are commercially available, though a number of laboratories have 
developed their own in-house methods to reduce costs. 
The single point mutation assays are more sensitive for minor variants, but the 
variability around the codon of interest can decrease hybridization of primers and 
probes that are needed to detect specific mutations [66]. The biggest disadvantage of 
these tests is the limited number of mutations that can be detected [67] and the fact 
that new probes should be designed every time a new relevant mutation is 
discovered. Different techniques can be used to detect single point mutations. A 
selective PCR is done by performing two separate PCR reactions, one to amplify the 
wild-type sequence and the other to amplify the mutant sequence. The primers are 
specifically designed to hybridize with either the mutant or wild-type sequence. 
Amplification will only take place when the primer perfectly matches the target 
sequence [68]. In some studies, selective PCR for specific mutations were developed 
to detect mutations in minor populations [69, 70]. 
In the oligonucleotide ligation assay two differently labeled oligonucleotides are 
hybridized on a template. Only the oligonucleotide with the perfect match can be 
detected [66, 67, 71]. Several groups showed that this assay is more sensitive 
compared to population sequencing assays [72, 73], also for non-B subtypes [74]. 
 
1.6. HIV/AIDS and access to treatment in resource-limited countries 
Despite the worldwide efforts to address the AIDS epidemic, the number of people 
living with HIV and the number of deaths due to AIDS continues to rise. At the end of 
2007, about 33.2 million people were living with HIV, including 2.5 million newly 
infected adults and children. Unfortunately, resource-limited settings continue to carry 
the burden of the epidemic with 63% (24.7 million) and 20% (7.8 million) of all HIV-
infected adults and children living in Sub-Saharan Africa and South/South-East Asia 
respectively (figure 6) [1].  
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Figure 6: Adults and children estimated to be living with HIV in 2007 
Adapted from: www.unaids.org 
 
1.6.1. Scaling up access to antiretroviral therapy 
Access to ART in low and middle-income countries has expanded significantly in the 
last couple of years. Only 400 000 people in these countries received ART at the 
time when WHO and UNAIDS launched the “3 by 5” initiative (December 2003). By 
the end of 2006, the coverage of people in need of ART in low and middle-income 
countries increased from 7% to 28% (to more than 2 million people). The increase 
was most dramatic in sub-Saharan Africa (more than 10-fold) resulting in more than 
1.3 million people with access to ART today [75]. Figure 7 shows the rapid scale up 
of ART in Africa from 2002 to 2005, but also indicates the differences in progress 
between countries. 
Though the pharmaceutical industry is making efforts to reduce prices for ART and 
increase the availability of generic products, drugs for second-line treatment are still 
scarce in resource-limited settings compared to the Western world [76]. 
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Figure 7: People in sub-Saharan Africa receiving ART as a percentage of those in need, 2002-2005 
Adapted from: http://www.who.int/hiv/fullreport_en_highres.pdf 
 
1.6.2. Scaling up access to laboratory tools to monitor patients on ART 
Unfortunately, laboratory tools necessary to monitor patients on ART, are lagging 
behind. Traditionally, more financial resources are made available for the prevention 
and treatment of diseases, while almost no funding is available to improve laboratory 
capacity in order to ameliorate the services needed to monitor these patients [77]. 
Viral load tests, CD4+ T cell counts and even resistance tests are considered 
standard of care in the Western world [36-38]. These assays can help the clinicians 
to decide when to start ART and when to switch a failing ART regimen to a salvage 
regimen. However, in some resource-limited settings, the combined cost of a 
commercial viral load assay and a CD4+ T cell count test exceeds twice the cost of 
one month ART [78]. 
According to the WHO guidelines to scale up ART in resource-limited countries, a 
CD4+ T cell count is desirable at baseline and every 6 months when on treatment 
[39]. A total lymphocyte count (TLC), possibly combined with the haemoglobin level, 
has been suggested as an alternative for a CD4+ T cell count. This routine test has 
been shown feasible to guide decisions on when to start ART [79, 80], but the 
predictive value of TLC for the response to ART is doubtful [81, 82]. Fortunately, the 
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CD4+ T cell tests are becoming more and more available although the supply of 
reagents remains challenging in most places. Moreover, some studies show a 
significant misclassification of therapeutic responses based on clinical and 
immunological criteria only [83-87], therefore viral load assays remain the preferred 
parameter to assess treatment responses.  
Four commercial HIV-1 viral load assays are currently licensed by the FDA (Roche 
Amplicor HIV-1 Monitor, Biomérieux Nuclisens HIV-1 QT, Versant HIV-1 RNA 3.0 
and Abbott RealTime HIV-1), with prices varying between 50 and 100 USD per test. 
Some companies have made a commitment to lower their prices for viral load assays 
in resource-limited settings, but the implementation of these tests remains 
problematic due to poor lab infrastructure and lack of trained personnel. Viral load 
assays are not only needed to detect treatment failure, but can also be useful to 
monitor patients’ adherence to ART [45, 46] and to diagnose perinatal infection in 
children younger than 18 months [88-90]. It is therefore extremely important to 
develop cheap and easy alternative assays for viral quantification. Some low-cost 
alternative viral load assays have been developed in recent years. The p24 antigen 
(Ag) assay (Perkin-Elmer) was the first alternative test proposed for measuring the 
HIV-1 viral load [91]. Although initial results were promising [91-98], some conflicting 
results arose over the years [99-101]. Despite the doubtful use of this assay to 
monitor HIV-1 infected patients, p24 Ag determination remains a recommended 
assay for the diagnosis of perinatal HIV infection [102-107]. Another alternative for 
HIV viral load measurement is the ExavirLoad (Cavidi). A high sensitivity and 
specificity was found by several groups assessing this assay [94, 98, 108-113] and 
some showed the feasibility of this assay to monitor patients on ART treatment [98, 
108, 109]. However most studies were conducted in well-equipped laboratories and 
in collaboration with the manufacturer. A third group of alternative viral load assays 
are the home-made real-time PCR assays. Lewin et al. were the first to describe an 
in-house real-time PCR assay to detect HIV-1 RNA [114] and others showed that the 
quantification of HIV-1 RNA by real-time PCR was feasible [115-120]. Rouet et al, 
found their in-house real-time PCR assay to be suitable for patient monitoring and 
paediatric diagnosis in Ivory Coast [119]. Based on these good results, a French 
company (Biocentric) decided to produce a Generic HIV viral load kit to quantify HIV-
1 RNA. Performance data of ExavirLoad and Generic HIV viral load assays in 
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resource-limited settings are still limited and more studies are needed to confirm 
these promising results. 
WHO does not recommend the use of genotypic resistance assays because their 
guidelines advise to change all components of the regimen in case of failure [39]. 
However, due to the limited availability of second-line ARV drugs in resource-limited 
settings, replacing all components of the first-line regimen is often impossible and 
recycling of drugs for a second-line regimen remains the only option. In this case, the 
efficiency of the second-line regimen will definitely improve if the choice of drugs can 
be guided by resistance testing. The need for drug resistance assays will increase 
even more when the number of available ARV drugs in resource-limited settings 
increases and third-line regimens become an option. The lack of viral load 
determinations as a parameter for early treatment failure, will increase  
the risk of accumulating resistance mutations leading to possible cross-resistance. 
This does not only pose a problem to the individual patient, but also increases the 
risk of transmission of highly resistant viruses in the population. Efforts to monitor the 
spread of resistant virus are therefore necessary. At this moment, the laboratories 
are not equipped to perform such high-skilled tests and the patients and health care 
systems lack the financial means to pay for these tests. However, at this moment it 
would be unethical to recommend resistance testing for individual patient follow-up 
as most patients don’t even have access to viral load assays. Therefore WHO has 
initiated an HIV Drug Resistance Surveillance Program that can signal when the 
transmitted HIV drug resistance requires action in a particular region. The obtained 
information can be used to assess whether the country’s standard ART regimens will 
continue to be effective, to evaluate the effects of post and pre-exposure prophylaxis 
and to give information about resistance to researchers who are developing 
prevention methods such as vaccines and microbicides.  
Besides the technical, logistical and economical obstacles to implement treatment 
monitoring assays in resource-limited countries, sample collection, transportation and 
storage remain another challenge. Many sites lack a stable electricity supply, 
whereby the use of centrifuges, freezers and ACs is hampered. Due to these 
constraints it is often difficult obtain high quality samples that were appropriately 
processed and stored. In this respect the dried blood spots (DBS) are an ideal 
medium to collect samples in the field. This type of specimens is easy to collect by a 
simple finger prick, they can be air-dried and stored at room temperature until 
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transportation to a central laboratory. Also transportation of these samples is 
simplified because no dry ice shipment is required, as they can be sent my general 
air-mail, without the risk of infection. 
Although the expansion of global access to ART should remain a priority, affordable 
and simple tools to assess the response to treatment are equally important. 
 
1.7. Description of the research site 
1.7.1. Mombasa, Kenya 
Kenya is an East-African country bordered by Somalia, Ethiopia, Sudan, Tanzania 
and Uganda (Figure 8). The country’s main foreign exchange earner is tourism. This 
is followed closely by agricultural exports such as coffee, tea and horticultural 
products. Almost 50% of the 35 million Kenyans live below the poverty line of 1 US$ 
per day. 
Mombasa is a coastal island about 500 km from the capital Nairobi. It is the second 
largest metropolis in Kenya, with about 500,000 inhabitants It harbours the largest 
port in East-Africa, not only serving Kenya, but also the East-African hinterland 
(Uganda, Burundi, Rwanda and the Eastern part of the Democratic Republic of 
Congo). Mombasa has an interesting culture mix with most inhabitants being African, 
Arab or Swahili and a minority of Indians and Europeans. 
 
 
Figure 8: Map of Kenya 
Adapted from: https://www.cia.gov/cia/publications/factbook/geos/ke.html 
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Although recent data indicate that the prevalence among adults living with HIV in 
Kenya dropped from 10% in the late nineties to 7% in 2003 [121] to just over 5% 
today, the prevalence in some areas is still as high as 13%. Overall 1 million 
Kenyans are currently living with HIV [122]. About 44% of the HIV-infected Kenyan 
people in need of ART receive treatment. The numbers have increased from 3 000 in 
2002 to 125 000 2006 [75]. Currently all provincial hospitals and 70 district hospitals 
in Kenya provide comprehensive HIV care, including counseling, prevention and 
treatment of opportunistic infections, as well as delivery of antiretroviral treatment. 
The goal is to reach 75% of the people needing ART by 2010. 
 
1.7.2. International Centre for Reproductive Health (ICRH) 
The International Centre for Reproductive Health (ICRH) was established in 1994 
after the International Conference on Population and Development (Cairo, 1994). 
ICRH is a multidisciplinary centre operating within the Faculty of Medicine and Health 
Sciences at the Ghent University. In addition to research and training activities, ICRH 
is involved in the implementation of development-related projects in Africa, Asia and 
Latin-America. The objective of ICRH is to improve the acceptability, accessibility and 
quality of sexual and reproductive health services, and integrate gender sensitive and 
human rights based approaches in the analyses. Since 2004, ICRH is recognized as 
a ‘WHO Collaborating Centre for Research on Sexual and Reproductive Health’. 
In 2000, ICRH Mombasa was registered as a non governmental organization (NGO) 
in Kenya. ICRH Mombasa is dedicated to health interventions and research for the 
well-being of the Kenyan population, in particular in the Coast Province. The NGO 
has grown from a small project-oriented organization to a full-fledged Kenyan 
organization with over 100 staff members. Participation of Kenyan scientists and 
managers in all levels is constantly on the rise. ICRH is collaborating closely with the 
University of Nairobi and public sector institutions in Coast Province, particularly with 
the Coast Province General Hospital (CPGH), the Provincial Medical Officer and the 
Mombasa City Council. 
Activities in Mombasa involve sexually transmitted infections (STI) and HIV 
prevention, treatment and care, including projects on behaviour-change interventions 
in most-at-risk populations, prevention of mother to child transmission of HIV, and 
female initiated prevention methods. CPGH, the second largest public hospital in 
Kenya, provided the opportunity and facilities to conduct the research. Capacity 
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building of CPGH is provided through technical advice, regular trainings for local 
health staff (doctors, nurses, laboratory technologists etc.), infrastructural support (a 
gender based violence clinic was recently built and a new biochemistry laboratory 
unit has been planned), as well as collaborations in clinical trial conduct. 
Samples used for this research were collected at CPGH and processed and stored in 
the ICRH laboratory. Other samples were sent to the AIDS Reference Laboratory in 
Ghent, Belgium. The AIDS Reference Laboratory is an accredited laboratory, where 
HIV-infected patients are being monitored. ICRH has a close collaboration with this 
laboratory for various of their research activities. 
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1.8. Research Objectives 
As previously described there is an urgent need to develop simple and affordable 
alternatives for the current viral load and resistance assays, which can be 
implemented in resource-limited settings.  
Therefore, the overall objective of this work is to evaluate existing and develop 
alternative methods for viral load and genotypic resistance assays, suitable for future 
use in resource-limited settings. 
 
Specific objectives include: 
1) to test simple and low-cost alternative viral load assays in a public hospital 
with limited treatment monitoring facilities 
2) to study an in-house genotyping system to detect drug resistance 
mutations  
3) to assess the feasibility of using dry blood spots for the detection of these 
mutations in order to simplify the sample collection and transportation 
process 
4) to examine the treatment success and the prevalence of drug resistance 
among patients receiving ART at a public hospital with limited treatment 
monitoring facilities 
 
In addition we attempted to strengthen the local laboratory at Coast Province General 
Hospital and to set-up a research laboratory where viral load assays could be 
performed. 
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Pictures ICRH 
 
 
 
ICRHK Laboratory at Coast Province General Hospital, Mombasa 
 
 
 
 
  
ICRHK-day at the beach 
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Chapter II: Results 
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Abstract
There is an urgent need for low-cost assays for HIV-1 quantitation to ensure adequate follow-up of HIV-infected patients on antiretroviral
therapy (ART) in resource-limited countries. Two low-cost viral load assays are evaluated, a reverse transcriptase activity assay (ExavirLoad v2,
Cavidi) and a real-time reverse transcriptase PCR assay (Generic HIV viral load, Biocentric). Both tests were compared with the ultrasensitive
HIV Amplicor Monitor assay. Samples were collected in Mombasa, Kenya, from 20 HIV-1 seronegative and 150 HIV-1 seropositive individuals
of whom 50 received antiretroviral treatment (ART). The ExavirLoad and the Generic HIV viral load assay were performed in a local laboratory
in Mombasa, the Amplicor Monitor assay (version 1.5, Roche Diagnostics) was performed in Ghent, Belgium.
ExavirLoad and Generic HIV viral load reached a sensitivity of 98.3% and 100% and a specificity of 80.0% and 90.0%, respectively. Linear
regression analyses revealed good correlations between the Amplicor Monitor and the Generic HIV viral load (r = 0.935, p < 0.001) with high
accuracy (100.1%), good precision (5.5%) and a low percent similarity coefficient of variation (5.4%). Bland–Altman analysis found 95% of
the samples within clinically acceptable limits of agreement (−1.19 to 0.87 log copies/ml). Although, the ExavirLoad also showed a good linear
correlation with the Amplicor Monitor (r = 0.901, p < 0.001), a problem with false positive results was more significant. The cost per test remains
relatively high (US$ 30 for ExavirLoad and US$ 20 for the Generic HIV viral load). Hence, false positive results and the need for an expensive
PCR instrument for the Generic HIV viral load assays still limit the implementation of these tests in less equipped, less experienced laboratories.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Programs to scale-up ART in resource-limited countries have
received a lot of attention in the last 3 years (WHO, 2006a). Cur-
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rently, almost 1.5 million people in these countries are receiving
ART and the numbers continue to grow. Due to limited resources
and inadequate laboratory capacity, many programs have mini-
mized the laboratory monitoring of patients on treatment, in an
effort to accelerate the widespread availability of the antiretrovi-
ral drugs (Petti et al., 2006). There are, however, several reasons
why equal efforts should be made to implement HIV-1 RNA
viral load monitoring in these regions. The inability to detect
early virological failure could lead to an accumulation of resis-
tant mutations and the selection of viruses with broad cross
resistance to antiretrovirals. An increasing number of patients
carrying drug resistant virus will inevitably lead to a spread of
these resistant strains in the population. Moreover, recent studies
have shown that determination of the viral load, in combination
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with an adherence intervention, can assist patients in maintain-
ing their first-line regimen, preventing unnecessary switches in
treatment (Boulle et al., 2006; Reynolds et al., 2006). In addition,
viral load assays, when cheaper and more user-friendly, could
be used to assess ART program quality, and are a useful tool for
early diagnosis of perinatally infected children (Delamare et al.,
1997; Lambert et al., 2003; Rouet et al., 2001; Simonds et al.,
1998).
Broadly used commercial viral load assays such as the
Roche Amplicor HIV-1 Monitor, Bayer Versant HIV-1 RNA,
BioMe´rieux Nuclisens HIV-1 QT and the Abbott real-time HIV-
1 PCR assays remain too expensive (US$ 50–100 per test)
(Fiscus et al., 2006; Stephenson, 2002). Recently, two more
affordable viral load assays became available: the ExavirLoad
assay which determines the activity of the reverse transcrip-
tase (RT) enzyme as a marker of retroviral replication, and the
Generic HIV viral load test which is a real-time PCR assay,
measuring the HIV-RNA burden in plasma. The performance
of these assays was compared with the Roche Amplicor HIV-1
Monitor 1.5 assay. Both alternative viral load assays were eval-
uated in Coast Province General Hospital in Mombasa, Kenya.
The Roche Amplicor Monitor assay was performed in Ghent,
Belgium.
2. Materials and methods
2.1. Patients and samples
All study participants were recruited from Coast Province
General Hospital in Mombasa, the second largest public hospital
in Kenya. A total of 150 adult HIV-1 infected patients attend-
ing the HIV comprehensive care centre (CCC) were selected
at random. The CCC was set-up to launch the ART program
in Mombasa. Of the selected patients, 50 were on ART and
100 were treatment naı¨ve. Additionally, 20 HIV-seronegative
patients were selected at random after voluntary testing and
counselling at the CCC or the antenatal clinic. Written informed
consent for participation in the study was obtained from all 170
study participants. The study was approved by the ethics review
committee of the University of Nairobi.
The mean age of the HIV-1 seronegative subjects was 27.5
years (S.D. ± 5.9), 16 (80.0%) of them were women. The mean
age of the HIV-1 infected patients was 36.9 (S.D. ± 9.2) years,
99 (66.0%) were women and 51.3% of all infected patients
were in clinical stage 3 or 4 (WHO, 2006b). Median CD4
cell counts, available for 143 of the HIV-infected patients, was
243 cells/mm3 (IQR 138–405 cells/mm3). Patients on ART were
on treatment for a mean of 13 months (ranging from 2 weeks to
33 months).
Ten millilitres of EDTA blood was collected for CD4
cell count (FACScount Becton Dickinson Immunocytometry,
Oxford, UK). The remainder of the EDTA blood was centrifuged
to collect the plasma which was stored in three different aliquots
at −80 ◦C until processing. Two aliquots were used in Mombasa
to perform the ExavirLoad and the Generic HIV viral load test.
One aliquot was shipped to the AIDS Reference Laboratory
at the Ghent University Hospital, Belgium, where the Amplicor
Monitor assay (Roche Diagnostics, Basel, Switzerland) was per-
formed.
2.2. ExavirLoad version 2 Cavidi assay
HIV-1 RT activity in plasma samples was assessed in
Mombasa, using the ExavirLoad version 2 kit (Cavidi Tech
AB, Uppsala, Sweden, Lot Nos. 05052 and 06018) follow-
ing manufacturers’ instructions. Results were evaluated using
the ExavirLoad Analyser version 1.1 software. The assay mea-
sures the activity of the HIV RT enzyme in converting RNA
to cDNA. A virus binding gel is added to 1 ml of plasma
to purify the virus particles. After removing inhibitors such
as RT inhibitor drugs and antibodies by washing steps, the
viruses are lysed. The lysates are subsequently transferred to
a 96-well plate for the RT activity assay. During an overnight
incubation, the RT enzyme incorporates BrdUTP into a DNA
strand complementary to a polyA template bound to the wells.
An anti-BrdUTP antibody conjugated to alkaline phosphatase
is added and the amount of incorporated BrdUTP is detected
using a substrate. The colour intensity of each well is read
using a standard plate reader at 405 nm. Results are extrapo-
lated against a standard curve, expressing the HIV RT activity
in fg/ml. The RT activity is automatically converted to HIV
RNA copies/ml equivalents using the ExavirLoad Analyser
software. The lower detection limit (LDL) of this assay is
400 copies/ml.
2.3. Generic HIV-1 viral load Biocentric assay
The Generic HIV viral load assay (Biocentric, Bandol,
France, Lot Nos. 1298307 and 1401633) was also performed
in Mombasa. The principle of real-time PCR is based on a flu-
orogenic 5′ nuclease assay: a probe with a reporter dye at the
5′-end and a quencher dye at the 3′-end is cleaved during the
amplification reaction. As the reporter dye gets separated by
the quencher dye, an increased fluorescence of the reporter is
detected. The fluorescence is directly proportional to the initial
amount of RNA present in the sample. The software produces a
threshold cycle (Ct-value) from each raw fluorescence data and
extrapolates that against a standard curve.
HIV-1 RNA was extracted from 200l of plasma using
the QIAamp Viral RNA mini kit (QIAgen, GmbH Germany,
Lot No. 1014795). The volumes of AVL buffer and absolute
ethanol were increased as per manufacturers’ instructions. Final
elution was done in 60l of Molecular Biology Grade water
(Sigma–Aldrich, Bornem, Belgium).
The Generic HIV viral load kit was used for further RT-PCR
amplification. The RT-PCR targets a conserved consensus region
in the long terminal repeat (LTR) region of HIV-1. Samples were
first tested according to the manufacturer’s instructions (referred
to as ‘standard method’), in a total reaction volume of 50l
containing 20l of RNA, 25l master mix and 1l each of
the two primers, the probe, the reference dye and the enzyme.
To reduce costs, a modified version of the assay, in which the
volume of all reagents was reduced by half, was also evaluated
(referred to as ‘modified method’).
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A standard curve was constructed with serial 10-fold dilu-
tions (from 5,000,000 to 500 copies/ml) of the standard sample
included in the kit. The cycling conditions were 30 min at 48 ◦C
and 10 min at 95 ◦C, followed by 50 cycles of 95 ◦C for 15 s
and 60 ◦C for 1 min. Amplification and data collection were car-
ried out using the ABI Prism 7000 Sequence Detection System
(Applied Biosystems, South Africa). The Generic HIV viral load
assay has a LDL of 300 copies/ml.
2.4. Roche Amplicor HIV-1 Monitor 1.5 assay
The Ultrasensitive Cobas Amplicor HIV-1 Monitor Test
version 1.5 (Roche Diagnostics, Basel, Switzerland, Lot No.
H02784) with a lower detection limit of 50 copies/ml was used
as a reference method and performed according to the manu-
facturer’s instructions (Sun et al., 1998). All Cobas Amplicor
Monitor analysis were run in Ghent, Belgium.
2.5. Subtyping
Protease (PR) and reverse transcriptase (RT) gene sequences
were obtained using a home-made sequencing assay as described
earlier (Steegen et al., 2006). Direct sequencing of both sense
and antisense strands was done with the dRhodamine Termina-
tor Cycle Sequencing Ready Reaction kit (Applied Biosystems,
Foster City, CA, USA). Sequencing reaction products were
analysed on an ABI310 or an ABI3130XL Genetic Analyser
(Applied Biosystems). All validations and subsequent manipu-
lations of the sequencing results as well as the interpretations of
the genotyping data and the subtyping, were performed using
the SmartgeneTM HIV software packages (Integrated Database
Network System, Smartgene, Zug, Switzerland).
2.6. Statistical analysis
All statistical analyses were performed using SPSS 15.0
(SPSS, Illinois, USA). In order to avoid bias caused by dif-
ferent upper and lower detection limits viral load results above
100,000 copies/ml were equalized to 100,000 copies/ml (5log
copies/ml). The lower viral load values obtained with Amplicor
Monitor were adapted according to the comparator assay.
When the Generic HIV viral load data set was analysed, the
Amplicor Monitor viral load results <300 copies/ml (LDL of
Generic HIV viral load) were equalized to 300 copies/ml. When
the ExavirLoad data set was analysed, all Amplicor Monitor
results <400 copies/ml were equalized to 400 copies/ml (LDL
of ExavirLoad). All results below the LDL of an assay, were
set at half the LDL value, i.e. 150 copies/ml (log = 2.2) for
Generic HIV viral load and 200 copies/ml (log = 2.3) for Exavir-
Load. The normality of data distribution was examined by the
Smirnov–Kolmogorov test. Direct correlations between the dif-
ferent data sets were measured with a two-tailed Spearman rank
correlation. A Bland–Altman difference plot was generated for
bias and agreement measurements, including limits of agree-
ment (Bland and Altman, 1999). A percent similarity model
was applied to determine accuracy, precision and an overall
agreement between two assays (Scott et al., 2003). Tab
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To assess a possible influence of different subtypes on the
outcome of the viral load assays, an independent two tailed t-test
was used.
3. Results
3.1. Speciﬁcity and sensitivity of the assay
Only the Amplicor Monitor assay gave an undetectable viral
load result for all 20 samples from HIV-negative individuals.
Positive results were obtained in one patient by the standard
Generic HIV viral load (1432 copies/ml), in two patients by
the modified Generic HIV viral load (673 and 724 copies/ml)
and in four patients in the ExavirLoad (407, 432, 900 and
3174 copies/ml), resulting in a specificity of 95.0% (95% CI:
73.1–99.7%), 90.0% (95% CI: 66.9–98.2%) and 80.0% (95%
CI: 55.7–93.4%), respectively (Table 1).
Of the 31 HIV seropositive patients on ART with an unde-
tectable viral load in the Amplicor Monitor assay (Table 1), 30
and 27 had a viral load below the detection limit by the stan-
dard and modified Generic HIV viral load, respectively. Only
12 patients had an undetectable viral load by ExavirLoad. Of
note, three out of four patients for whom a positive result was
obtained with the Generic HIV viral load also scored positive
in ExavirLoad. For most of the samples the viral load remained
low, ranging from 413 to 3833 copies/ml in Generic HIV viral
load and from 404 to 3410 copies/ml in ExavirLoad. One treat-
ment naı¨ve patient had an undetectable viral load in all three
assays.
Of the 150 specimens from HIV-infected individuals, 118
(78.6%) had a detectable viral load in the Amplicor Monitor
assay (Table 1). Of those, 111 and 113 were detectable with
the standard and the modified Generic HIV viral load assay,
respectively. In the ExavirLoad, 113 samples were detectable.
The seven samples with a detectable viral load in the Amplicor
Monitor assay that remained undetectable in the Generic HIV
viral load assay, had Amplicor Monitor viral load results below
the detection limit of the Generic HIV viral load assay (55, 73,
74, 81, 128, 159 and 294 copies/ml) and therefore can not be
considered as false negative. The five samples with a detectable
viral load in the Amplicor Monitor assay but with an unde-
tectable result in ExaVirLoad had an Amplicor Monitor viral
load of 55, 73, 74, 9790 and 15,300 copies/ml. The latter two
were clearly above the detection limit of the assay and must
be considered as false negative in ExaVirLoad. This results in
a sensitivity of 100% (95% CI: 95.9–100%) and 98.3% (95%
CI: 93.2–99.7%), for Generic HIV viral load and ExavirLoad,
respectively.
Fig. 1. Comparison between the results of the Generic HIV viral load assay (standard method) and the Amplicor Monitor assay. All samples with a viral load
<300 copies/ml were equalized to 150 copies/ml (2.2log). (A) Direct assay correlation between Amplicor Monitor and Generic HIV viral load. Spearman correlation
r = 0.935 (p < 0.001). (B) Bland–Altman difference plot with the difference between Amplicor Monitor and Generic HIV viral load (Y-axis) against the Amplicor
Monitor results (X-axis). The bias on the difference is −0.16 (S.D.: 0.54) with limits of agreement between −1.19 and 0.87. (C) Percent similarity plot with 100.1%
accuracy, 5.5% precision and a coefficient of variance of 5.4%.
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Table 2
Summary of the results of the statistical analysis
Direct assay correlation Bland–Altman plot Percent similarity plot
Spearman
coefficient
p-Value Bias (mean) S.D. Limits of
agreement
Accuracy
(mean)
Precision
(S.D.)
Overall
agreement (CV)
Generic HIV viral load (50l) n = 150 0.935 <0.001 −0.16 0.53 −1.19 to 0.87 100.1% 5.5% 5.4%
Generic HIV viral load (50l) n = 63
(trimmed)
0.835 <0.001 0.03 0.54 −1.02 to 1.08 100.3% 7.1% 7.1%
Generic HIV viral load (25l) n = 150 0.939 <0.001 0.01 0.29 −0.56 to 0.58 100.6% 4.8% 4.8%
Generic HIV viral load (25l) n = 63
(trimmed)
0.902 <0.001 0.02 0.40 −0.77 to 0.80 100.8% 6.2% 6.1%
ExavirLoad n = 150 0.901 <0.001 −0.03 0.51 −1.03 to 0.96 100.8% 7.8% 7.7%
ExavirLoad n = 63 (trimmed) 0.787 <0.001 −0.15 0.58 −1.29 to 0.98 98.9% 8.1% 8.2%
S.D.: Standard deviation, CV: coefficient of variance.
3.2. Correlation between Generic HIV viral load and
Amplicor Monitor assays
Standard Generic HIV viral load results and Roche Amplicor
results were available for all 150 patients. Forty-nine had a viral
load >100,000 copies/ml and 31 were undetectable in both (with
Amplicor Monitor LDL set at 300 copies/ml). In 40 samples a
higher viral load value was found by Generic HIV viral load
compared to Amplicor Monitor, whereas in 30 of the sam-
ples the Generic HIV viral load result was lower. Differences
in log copies/ml were <0.5 and thus within the normal range
of the test variability for most of the samples (n = 49). For 21
samples, the difference ranged from 0.50 to 2.16 log copies/ml.
As shown in Fig. 1A, a good correlation was found between
the results of both assays (Spearman correlation coefficient of
r = 0.935; p < 0.001). In the trimmed data set, with exclusion
of results above and below the detection limit, the correlation
decreased to r = 0.835, but remained statistically significant.
The agreement between the two assays was assessed by a
Bland–Altman plot and the percent similarity model. Results are
shown in Fig. 1B and C. When the modified version of Generic
HIV viral load assay was compared to the Amplicor Monitor
assay a comparable correlation coefficient was found (r = 0.939).
The results of additional statistical analysis are summarized in
Table 2.
3.3. Correlation between ExavirLoad and Amplicor
Monitor assays
ExavirLoad and Amplicor Monitor results were avail-
able for all 150 patients. Forty-two had a viral load above
100,000 copies/ml and 16 were undetectable in both assays
(with LDL Amplicor Monitor set at 400 copies/ml). In 56 sam-
ples, the difference in log copies/ml between both results was
<0.5. In 11 patients the difference exceeded 1.0 log. For five
of these, the viral RNA was either undetectable or above the
HDL in one of the two assays. Overall, the results of both
assays correlated well, with a Spearman correlation coefficient
of r = 0.901 (p < 0.001) for the untrimmed data (Fig. 2A) and
r = 0.787 (p < 0.001) for the trimmed data set, with exclusion of
results above and below the detection limit. The results of the
Bland–Altman and percent similarity plot are shown in Fig. 2B
and C and in Table 2.
3.4. Correlation between Generic HIV viral load assay,
standard and modiﬁed version
All samples from the 150 seropositive patients were run both
with the standard Generic HIV viral load assay and a modified
version with a reaction volume reduced to 25l. Thirty-nine
and 33 samples were found with an undetectable viral load in
the standard and modified assay, respectively. For 26 samples,
the log difference between the viral load results of both versions
was greater than 0.5, but the difference exceeded 1.0log in only
5. A good correlation was found between the results of both
assay versions, with a Spearman correlation coefficient of 0.937
(p < 0.001) (Fig. 3A). Fig. 3B and C show the results of additional
statistical analysis.
3.5. HIV-subtype distribution and inﬂuence of the HIV
subtype on the results of the viral load assays
Sequencing data of the protease (PR) and (RT) gene were
available for 56 out of the 60 patients for whom the sequence
analysis was attempted, including all 50 patients on ART and
10 selected at random from the 100 treatment naı¨ve patients.
Proviral DNA was used for the sequencing reactions, allowing
the subtyping of samples irrespective of the RNA viral load.
Results revealed a subtype distribution as follows: subtype A,
55.4% (n = 31), D, 12.5% (n = 7), CRF16 AD, 12.5% (n = 7), C,
10.7% (n = 6), G, 1.8% (n = 1) and recombinations of mainly D,
A, C and CRF AE 7.1% (n = 4).
Table 3 shows the results of the three viral load assays for
the 56 patients for whom a subtyping was performed. For some
samples an undetectable viral load was observed in the Amplicor
Monitor and the Generic HIV viral load while a positive result
was obtained in ExaVirLoad. This discordance was observed
more frequently in samples with a subtype D (2 out of 2) or
C infection (5 out of 6), than in samples with subtype A virus
(5 out of 12). An independent, two-tailed t-test, comparing the
results of subtype A samples (n = 31) and non-subtype A sam-
ples (n = 25) showed no statistically significant subtype influence
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Fig. 2. Comparison between the results of the ExavirLoad assay and the Amplicor Monitor assay. All samples with a viral load <400 copies/ml were equalized
to 200 copies/ml (2.3log). (A) Direct assay correlation between Amplicor Monitor and ExavirLoad. Spearman correlation r = 0.901 (p < 0.001). (B) Bland–Altman
difference plot with the difference between Amplicor Monitor and ExavirLoad (Y-axis) against the Amplicor Monitor results (X-axis). The bias on the difference is
−0.03 (S.D. = 0.51) with limits of agreement between −1.03 and 0.96. (C) Percent similarity plot with 100.8% accuracy, 7.8% precision and a coefficient of variance
of 7.7%.
(p = 0.645 for the Generic HIV viral load and p = 0.699 for the
ExavirLoad).
4. Discussion
The challenge of how to appropriately monitor patients on
antiretroviral treatment in resource-limited settings was only
raised a few years ago with the increasing availability of ART
in these regions (Majchrowicz, 2003). In Western countries,
follow-up of HIV infected individuals includes at least regular
CD4 cell counts and viral load quantitations, supplemented with
genotypic resistance testing in case of treatment failure (CDC,
2006). Implementation of this procedure in resource-limited set-
tings will far exceed the available budgets. In some countries, the
combined cost of a CD4 cell count and a viral load test is higher
than the cost of 2 months ART therapy (Stephenson, 2002).
A number of alternative methods for viral load testing, includ-
ing p24 antigen detection, reverse transcriptase activity testing
and real-time PCR assays for viral RNA quantitation, have been
evaluated by others (Fiscus et al., 2006) and good correlations
were found between these assays and standard commercial viral
load tests. However, most of these studies were performed in
high-income countries and therefore did not take into account
the possible logistical problems that might be encountered in
resource-limited settings. In the study presented here, the assays
were performed on-site, in the Coast Province General Hospi-
tal, a public provincial referral hospital in Mombasa. Despite
the fact that all reagents had to come from overseas, delivery
went fairly well, which is partly due to the fact that reagents for
the assays can be bought together as a complete kit. Only the
QIAgen extraction kit for the Generic HIV viral load assay had
to be purchased separately.
The results of the assessed assays correlated well with the
Amplicor Monitor, with Spearman correlation coefficients of
r = 0.935 for the Generic HIV viral load and r = 0.901 for the
ExaVirLoad. The Generic HIV viral load showed a smaller bias
and narrower limits of agreement, compared to the ExavirLoad
assay. Besides, the precision and overall agreement with the
Amplicor Monitor was higher for the Generic HIV viral load
compared to the ExavirLoad assay. Large confidence intervals
for specificity of the evaluated assays compared to the Amplicor
Monitor were mainly due to the small sample size of HIV-
negative individuals. This must be seen as a limitation of the
study.
A relatively high number of false positive results were
observed, both in the small group of HIV negative individuals
and in the group of patients on a successful ART regimen accord-
ing to the Amplicor Monitor viral load results. Only 38.7% of
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Fig. 3. Comparison between the results of the Generic HIV viral load assay, using the standard and modified method. All samples with a viral load < 300 copies/ml
were equalized to 150 copies/ml (2.2log). (A) Direct assay correlation between methods 1 and 2. Spearman correlation r = 0.937 (p < 0.001). (B) Bland–Altman
difference plot with the difference between the standard and modified method (Y-axis) against the results of the standard method (X-axis). The bias on the difference
is 0.01 (S.D.: 0.40) with limits of agreement between −0.84 and 0.85. (C) Percent similarity plot with 100.9% accuracy, 6.5% precision and a coefficient of variance
of 6.4%.
the samples from treated patients in which the viral load was
<50 copies/ml in Amplicor Monitor, had an undetectable viral
load in the ExavirLoad. Ninety-seven percent (96.8%) remained
undetectable in the Generic HIV viral load. Further analysis of
the specificity of both tests and especially of the ExavirLoad
assay, on a larger number of HIV negative and successfully
treated individuals, is needed. False positive results were low
viral loads in the majority of the cases.
Since the primary aim of viral load testing is the evaluation
of treatment efficiency, the possible occurrence of false positive
results in successfully treated patients is an important draw-
back. Increasing the cut off of the assay might be a possibility
to avoid patients being falsely classified as treatment failures,
but this would prevent the detection of real, early virological
failure. False positive results occurred less frequently in the
Generic HIV viral load assay. The Generic HIV viral load assay
is an amplification-based assay and does not contain an internal
decontamination step comparable to the UNG-decontamination
in the Amplicor Monitor. Although amplification and detection
is performed in a single, sealed plate, which reduces the risks
for contamination, false positive results due to PCR contamina-
tion cannot be excluded, especially in laboratories where strict
separation between sample processing area, pre´-PCR area and
amplification area is not obvious.
When developing assays for resource-limited countries, spe-
cial attention should be paid to the high genotypic diversity of
HIV in these regions. Subtyping was performed on a subset
of the samples used in this study and revealed the presence of
at least five subtypes and a number of unique recombinations.
The subtype distribution found was similar to what was previ-
ously described for the same region (Neilson et al., 1999; Yang
et al., 2004). No subtype-related differences were expected for
the ExavirLoad assay, as the measurement of the RT activity
is supposed to be independent of the HIV-subtype (Braun et
al., 2003; Jennings et al., 2005; Malmsten et al., 2003, 2005;
Seyoum et al., 2006; Sivapalasingam et al., 2005; Stevens et al.,
2005). Nevertheless, infections with subtype D and C virus were
associated with five and two false positive results, respectively.
Due to a small sample size for subtype D, C, CRF16 AD, F
and the recombinant forms, statistical analyses of single sub-
type specific differences was not possible. When grouping all
non-A subtypes, no statistically difference between the perfor-
mance of the ExavirLoad assay for subtype A and non-A was
observed (p = 0.699). Additional studies are needed to evaluate
the performance of the ExavirLoad assay for each of the subtypes
individually.
For the Generic HIV viral load assay, no effect of HIV subtype
on the performance of the test could be observed. This is in
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Table 3
Results of viral load assays according to subtype
Study no. Subtype Amplicor Monitor Generic HIV viral load ExavirLoad
VL (c/ml) VL (log c/ml) VL (c/ml) V (log c/ml) VL (c/ml) VL (log c/ml)
020 A >100,000 >5.00 >100,000 >5.00 >100,000 >5.00
133 A >100,000 >5.00 >100,000 >5.00 >100,000 >5.00
116 A >100,000 >5.00 >100,000 >5.00 79,150 4.90
018 A 35,400 4.55 55,272 4.74 68,850 4.84
139 A 26,300 4.42 4,811 3.68 2,526 3.40
028 A 21,600 4.33 55,472 4.74 11,655 4.07
011 A 16,900 4.23 51,926 4.72 42,350 4.63
141 A 10,400 4.02 1,000 3.00 1,866 3.27
016 A 5,330 3.73 2,367 3.37 3,056 3.49
106 A 3,520 3.55 6,802 3.83 1,186 3.07
144 A 2,520 3.40 5,152 3.71 4,104 3.61
132 A 2,260 3.35 2,524 3.40 485 2.69
127 A 1,690 3.23 630 2.80 2,119 3.33
102 A 1,250 3.10 8,196 3.91 5,490 3.74
113 A 1,030 3.01 1,000 3.00 1,914 3.28
145 A 294 2.47 <300 <2.48 2,140 3.33
039 A 159 2.20 4,811 3.68 1,179 3,07
142 A 128 2.11 <300 <2.48 463 2.67
021 A 73 1.86 <300 <2.48 <400 <2.60
101 A <50 <1.70 <300 <2.48 <400 <2.60
111 A <50 <1.70 <300 <2.48 <400 <2.60
119 A <50 <1.70 <300 <2.48 <400 <2.60
121 A <50 <1.70 <300 <2.48 <400 <2.60
130 A <50 <1.70 <300 <2.48 <400 <2.60
136 A <50 <1.70 <300 <2.48 <400 <2.60
143 A <50 <1.70 <300 <2.48 <400 <2.60
122 A <50 <1.70 <300 <2.48 3,410 3.53
134 A <50 <1.70 <300 <2.48 1,390 3.14
148 A <50 <1.70 <300 <2.48 1,301 3.11
118 A <50 <1.70 <300 <2.48 834 2.92
138 A <50 <1.70 <300 <2.48 408 2.61
030 C 66,300 4.82 43,205 4.64 40,125 4.60
105 C 21,000 4.32 10,576 4.02 14,690 4.17
120 C 81 1.91 <300 <2.48 1,272 3.10
131 C <50 <1.70 <300 <2.48 1,723 3.24
117 C <50 <1.70 <300 <2.48 494 2.69
103 C <50 <1.70 3,833 3.58 <400 <2.60
108 D 74 1.87 <300 <2.48 <400 <2.60
115 D <50 <1.70 <300 <2.48 <400 <2.60
129 D <50 <1.70 <300 <2.48 1,265 3.10
150 D <50 <1.70 <300 <2.48 1,113 3.05
110 D <50 <1.70 <300 <2.48 456 2.66
112 D <50 <1.70 <300 <2.48 421 2.62
109 D <50 <1.70 <300 <2.48 404 2.61
126 G <50 <1.70 <300 <2.48 989 3.00
002 CRF16 AD >100,000 >5.00 >100,000 >5.00 >100,000 >5.00
147 CRF16 AD 98,200 4.99 >100,000 >5.00 5,480 3.74
114 CRF16 AD 15,300 4.18 1,080 3.03 <400 <2.60
107 CRF16 AD 55 1.74 <300 <2.48 <400 <2.60
104 CRF16 AD <50 <1.70 <300 <2.48 <400 <2.60
125 CRF16 AD <50 <1.70 <300 <2.48 1,136 3.06
140 CRF16 AD <50 <1.70 <300 <2.48 490 2.69
010 A +D 9,790 3.99 7,415 3.87 <400 <2.60
123 A + D 3,060 3.49 518 2.71 2,810 3.45
137 AE + D <50 <1.70 <300 <2.48 <400 <2.60
128 A + C <50 <1.70 <300 <2.48 892 2.95
VL = Viral load, c/ml = copies/ml.
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agreement with other studies evaluating an in-house real-time
PCR assay that targeted the same Long Terminal Repeat (LTR)
region. The LTR region is one of the more conserved regions
of the HIV-1 genome and therefore perfectly suitable for the
development of assays with broad subtype specificity (Drosten
et al., 2006; Rouet et al., 2007, 2005).
The strength of the study presented here is that the assays
were evaluated in ‘field conditions’ and in an adequate number of
both ART naı¨ve and experienced patients. Only few other stud-
ies have addressed the use of the ExavirLoad or the Generic HIV
viral load assay or a comparable in-house LTR based real-time
PCR assay for the follow-up of adult patients on ART (Braun
et al., 2003; Greengrass et al., 2005; Stevens et al., 2005). They
concluded that both assays could be suitable to monitor treat-
ment in resource-limited countries. Sample sizes were, however,
very small and all these studies were conducted in well-equipped
laboratories which might explain the better performance of
these assays compared to the results presented here.
The observation of some false positive results in HIV-negative
patients might impair the use of the Generic HIV viral load assay
for diagnosis of perinatal HIV infection although an in-house
LTR based real-time PCR assay has also shown to be highly
sensitive and specific for early pediatric diagnosis (Rouet et al.,
2005).
When evaluating viral load tests in resource-limited settings,
one should not only take into account the performance of the test,
but also recurrent costs, availability of trained laboratory staff,
logistics for reagent delivery, accessibility of instrument servic-
ing and availability of external quality control programs. The
ExavirLoad assay has the advantage of a relatively cheap start-
up cost (US$ 3000) and maintenance free equipment. However,
the turn around time of the assay is long (2.5 days for 30 sam-
ples) and the test is very labor intensive. Even though the cost
per test (US$ 30) is lower than the current commercially avail-
able assays, it remains relatively high. To our knowledge, there
is no external quality control program available which includes
the ExavirLoad assay. A possible advantage of the test is the
option of using the left-over of the extracts in a kit for pheno-
typic resistance analysis (HIV Phenotype RT kit) (Shao et al.,
2003; Tuaillon et al., 2004).
The turn around time of the Generic HIV viral load assay is
low, allowing 48 samples to be run in one day. The cost per test
is about US$ 20 but can safely be reduced to US$ 10 by reducing
the recommended volume reagent as appeared from the results
described, although a more thorough evaluation of this adapta-
tion is needed. Purchasing and servicing of the PCR equipment,
however, remains a high cost to overcome. An advantage might
be that the same equipment can be used to perform other real-
time PCR assays like assays for the detection of other sexually
transmitted infections.
In conclusion, both the Generic HIV viral load assay and
the ExaVirLoad assay could be suitable tools for viral load
determination in resource-limited settings, yet both tests have
their limitations and should not be implemented without a thor-
ough on-site evaluation. Further research is needed to address
the influence of different subtypes on the performance on the
evaluated viral load assays, especially for ExavirLoad. More
research is needed to optimize the sensitivity and specificity of
low-cost viral load assays and to develop assays that are easy
to handle and require only a minimum of laboratory infrastruc-
ture and training. Meanwhile manufacturers of commercial viral
load assays should commit themselves to further simplify their
assays, reduce the prices and provide the necessary support in
infrastructure for their use in resource-limited settings.
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Abstract
Quantification of the viral burden and identification of drug resistant mutations are important laboratory tools in the management of HIV-1
infected patients. However, widespread use of assays for viral load determination and genotyping is still hampered by the high cost. Here, an
in-house RT-PCR-sequencing assay for HIV-1 drug resistance monitoring with the potential to be used both as a qualitative assay to detect the virus
in plasma and as a genotyping system is described. A total of 377 clinical samples, collected from 374 HIV-infected patients of diverse geographic
origin, were tested. The nested RT-PCR for amplification of the protease reverse transcriptase gene was found positive for 350 (92.8%) and 346
(91.8%) of 377 samples, respectively. All amplification-failures were due to viral loads of below 500 copies/ml. However, low viral load does not
exclude amplification since 80.2 and 76% of 121 samples with viral loads of less than 500 copies/ml were amplified successfully for protease and
reverse transcriptase, respectively. The high sensitivity of the assay was independent of the HIV-subtype, with a broad range of different HIV-1
subtypes tested. In conclusion the RT-PCR-direct sequencing method is convenient for the sensitive detection and subsequent genotyping of plasma
RNA from a broad range of different HIV-1 subtypes. The assay enables the accurate follow-up of patients under treatment at a significantly reduced
cost compared to the currently available commercial assays for viral load assessment and genotyping.
© 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Highly active antiretroviral therapy (HAART), based mainly
on combinations of reverse transcriptase (RT) and protease
(PR) inhibitors is widely used to treat human immunodeficiency
virus (HIV) infections. Whenever the virus is able to continue
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replication in the presence of these drugs, drug-resistant vari-
ants emerge, and the response to therapy is lost. Drug-resistant
variants that evolve during treatment can be transmitted from
one person to another and such spread of drug-resistant strains
through the population compromises the future use of any
antiretroviral drug (Hanna et al., 2003; Tang and Pillay, 2004).
Continuous monitoring of therapeutic effects and of develop-
ment of drug resistance in patients under therapy is therefore of
utmost importance.
Infrastructure and financial resources to ensure follow-up of
treatment, with regular measurements of the viral load and CD4
count and testing for drug resistance, are still lacking in most
parts of the world. Both, viral load assays and genotyping sys-
tems for detection of drug resistance are commercially available,
but their use in poorly resourced environments is hampered by
the high cost.
0166-0934/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
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The aim of this study was to design and evaluate a RT-PCR-
genotyping system for the sensitive amplification and sequenc-
ing of the protease (PR) and the reverse transcriptase (RT) gene
from a broad variety of different HIV-1 subtypes. Although
the main objective was to develop a low-cost alternative for
the commercial genotyping systems, the idea was also that a
very sensitive RT-PCR would allow combined screening for
viral replication in plasma and immediate sequencing of drug
resistance in the replicating virus. This might be the ideal com-
bination for a fast and low-priced monitoring of patients under
treatment.
2. Material and methods
2.1. Patients and samples
For this study, 377 samples from 374 HIV-1-infected patients
were selected. Two hundred and forty five samples were from
the patient cohort of the Aids Reference Center at Ghent Univer-
sity Hospital in Belgium. For 174 of these samples genotyping
was requested by the physician as part of the routine screen-
ing for baseline resistance in therapy naı¨ve patients (n = 106) or
because of indications for therapy failure (n = 68). The remain-
ing 71 samples were included because of viral loads below 500
copies/ml. In addition, 95 samples were obtained from treatment
naı¨ve patients visiting the Day Clinic of the Yaounde´ Central
Hospital, Cameroon, and 37 samples were from HIV-1 infected
therapy-naı¨ve women attending the Coast General Hospital in
Mombasa, Kenya. The latter samples were collected in the
non-intervention arm of a study performed during 1996–1999
examining the effect of vaginal lavage with diluted chlorhex-
idine on mother-to-child transmission (Gaillard et al., 2001).
Twelve samples with a viral load of <50 copies/ml were also
included.
Blood was collected in EDTA-treated tubes and the plasma
was stored at −20 to −80 ◦C before use. Plasma viremia was
quantified in the samples collected in Belgium and in Kenya
using the Cobas Amplicor Cobas Ampliprep HIV-1 Monitor
Assay, version 1.5 (Roche Diagnostics, Basel, Switzerland).
2.2. HIV RNA extraction
Viral RNA was extracted with the High Pure nucleic acid kit
(Roche Molecular Biochemicals, Mannheim, Germany). Virus
in the plasma was first concentrated by centrifugation of an
aliquot of 500l plasma at 23,600 × g at 4 ◦C for 1 h. After
removal of the plasma, the pellet was suspended in 200l
phosphate buffered saline (PBS). Subsequent extraction was
performed according to the manufacturer’s instructions with
a final elution of the RNA in 50l of the elution buffer.
In each extraction, a pool of HIV positive plasma samples,
diluted in negative plasma until a viral load of 1000 copies/ml
is obtained, is included as a positive control. Plasma from
a HIV negative blood donor is included as a negative con-
trol. The PCR result for the positive control has to be pos-
itive, otherwise all negative samples from that run must be
repeated.
2.3. Ampliﬁcation of HIV RNA by nested RT-PCR
An outer gag-pol RT-PCR product was obtained using
the Titan One tube RT-PCR system (Roche Molecular Bio-
chemicals, Mannheim, Germany) with a combination of four
primers. The RT-PCR was performed using 10l of puri-
fied viral RNA in a 50l volume reagent mix containing the
RT-PCR buffer, 100 mM dithiothreitol and 1l of the Titan
enzyme mixture (AMV reverse transcriptase, Taq DNA poly-
merase and Pwo DNA polymerase) and further supplemented
with 25 mM deoxynucleoside triphosphates (Amersham Bio-
sciences, Buckinghamshire, UK), 40 U/l of RNase inhibitor
(Promega Biosciences, San Luis Obispo, CA) and 0.1M
(each) of two forward primers (GAG2: 5′-GAGGAAGCT-
GCAGAATGGG-3′ and PR1: 5′-ATGATGCAGAGAGGCA-
ATTT-3′) and the two reverse primers (RT137: 5′-TTCTGTAT-
GTCATTGACAGTCCAGC-3′ and RT3303: 5′-TAAYTTYTG-
TATRTCATTGAC-3′). Primers were selected to have a broad
specificity for different HIV-1 subtypes.
The RT reaction was carried out at 45 ◦C for 30 min and 94 ◦C
for 2 min and immediately followed by the DNA amplification:
10 cycles at 94 ◦C for 30 s, 45 ◦C for 30 s and 68 ◦C for 1 min;
10 cycles at 94 ◦C for 30 s, 50 ◦C for 30 s and 68 ◦C for 2 min;
15 cycles at 94 ◦C for 30 s, 55 ◦C for 30 s and 68 ◦C for 3 min
and a final extension for 7 min at 68 ◦C.
A 2l volume of the outer RT-PCR products were used in
two separate inner PCR reactions, one with nested protease
primers (PR3: 5′-AGAGCCAACAGCCCCACCA-3′ and PR4:
5′-GGGCCATCCATTCCTGGCTT-3′) and one with nested
reverse transcriptase primers. (RT1: 5′-CCAAAAGTTAAA-
CAATGGCCATTGACAGA-3′ and RT4: 5′-AGTTCATAAC-
CCATCCAAAG-3′). The second-round PCR was carried out
using Taq polymerase (Applied Biosystems Incorporated, Fos-
ter City, CA) in a 50l reaction volume containing Taq buffer
II with 5 U/l of Taq Polymerase, 25 mM MgCl2, 1.25 mM
deoxynucleoside triphosphates (Amersham Biosciences, Buck-
inghamshire, UK) and 0.05M (each) of the specific forward
and reverse primers. The second-round PCR included an ini-
tial denaturation step at 94 ◦C for 5 min followed by 35 cycles
at 94 ◦C for 30 s, 50 ◦C for 30 s and 72 ◦C for 30 s and a final
extension for 7 min at 72 ◦C. The PR-primers amplify a 458 bp
fragment spanning the whole PR gene. The RT-primers amplify
a 646 bp fragment spanning the aminoacids 30 to 227 of the RT
gene.
A GeneAmp PCR system 9700 thermal cycler (Applied
Biosystems Incorporated, Foster City, CA) was used for all PCR
reactions. The results were checked by electrophoresis of the
nested PCR products on 1% agarose gels and visualized with
ethidium bromide under UV light.
2.4. Sequencing
The RT-PCR products, which showed a clear band on the
agarose gel, were purified by the QIAquick PCR Purification kit
(QIAgen, Venlo, The Netherlands). The purification was per-
formed according to manufacturer’s instructions with a final
elution in 50l of the elution buffer.
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Purified PCR products were subjected to direct sequenc-
ing of both the sense and antisense strands using the dRho-
damine Terminator Cycle Sequencing Ready Reaction kit v3.1
(Applied Biosystems Incorporated, Foster City, CA). For each
sample six separate sequencing reactions were performed using
respectively the four inner PCR primers (PR3, PR4, RT1
and RT4) and two additional internal RT primers: RT2882:
5′-GGGNGAYGCATATTTTTCARTWCC-3′ and RT2949: 5′-
CCTGGTGTYTCATTRTTTRYAC-3′. A 0.02M of each
primer was used in a 20l volume mix containing 3l of the
purified RT-PCR product, 3.5l 5× cycle sequencing dilution
buffer, 1l cycle sequencing reaction mix and 10l ultrapure
water. The sequencing PCR included 30 cycles of 95 ◦C for 30 s,
55 ◦C for 15 s and 60 ◦C for 4 min.
After running the sequencing reaction, non-incorporated
dideoxynucleoside triphosphates were removed by ethanol–
sodium acetate precipitation and the pellet was resuspended in
25l High Density Formamide (Applied Biosystems Incorpo-
rated, Foster City, CA) for denaturation and loading on the ABI
310 Genetic Analyzer (Applied Biosystems).
2.5. Validation, alignment and interpretation of sequencing
results
All validations and subsequent manipulations of the sequenc-
ing results as well as the interpretations of the genotyping
data were performed with software packages and genotyp-
ing algorithm programs that are freely available through the
internet.
Electropherogram patterns were displayed and manually
edited using ‘Chromas’ (http://www.technelysium.com.au/).
Assembly and alignment was done with the BioEdit software
package designed by Tom Hall (http://www.mbio.ncsu.edu/
BioEdit/bioedit.html). Interpretation of the sequences accord-
ing to resistance was performed using the Stanford HIV drug
resistance database (http://www.hivdb.stanford.edu/).
2.6. Phylogenetic analysis
Phylogenetic analyses and neighbor-joining tree recon-
structions were performed using programs from version
3.6 of the PHYLIP package (http://www.evolution.genetics.
washington.edu/phylip.html), with a maximum-likelihood dis-
tance matrix and a transition to transversion ratio of 2.0. Tree
diagrams were plotted with Treeview v1.4 (included in the
PHYLIP package).
3. Results
3.1. Nucleic acid extraction and nested RT-PCR
RNA extraction and RT-PCR was attempted on a total of
377 samples of which 245 were collected in Belgium, 95 in
Cameroon and 37 in Kenya. Viral load results were available for
all samples from Belgium and Kenya, and varied respectively
between 51 and >100,000 copies/ml (samples from Belgium)
and between 17,000 and >100,000 copies/ml (samples from
Fig. 1. Results of the RT-PCR for amplification of the protease gene. Neg, no
amplification; Pos, successful amplification.
Kenya). Viral load determination was not performed system-
atically for the samples from Cameroon.
Successful amplification of the PR region was obtained in
350 samples, 223 from Belgium, 90 from Cameroon and 37
from Kenya, resulting in an overall success rate of 92.8%. For
the RT region 346 samples were successfully amplified, 219
from Belgium, 90 from Cameroon and 37 from Kenya, result-
ing in an overall success rate of 91.8%. Of the 33 samples for
which amplification failed, viral load results were available for
28 and appeared to be very low (<500 copies/ml). Viral loads
were determined subsequently for the five additional samples
for which amplification failed. Results were <50 copies/ml for
three samples and respectively 204 and 424 copies/ml for the
remaining two.
Additionally 12 samples with a viral load of <50 copies/ml
were tested. All were found negative.
Although failure to amplify the PR and RT gene can occur
in samples with a viral load of below 500 copies/ml, the major-
ity (respectively 80 and 76%) of the 121 samples with a viral
load below 500 copies/ml that were tested were successfully
amplified for the PR and RT gene.
A summary of the RT-PCR amplification results for PR and
RT is shown in Figs. 1 and 2.
Fig. 2. Results of the RT-PCR for amplification of part of the reverse transcrip-
tase gene. Neg, no amplification; Pos, successful amplification.
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3.2. Genotyping
Sequencing of the 350 PR and 346 RT amplicons gave use-
ful sequence data for all. A sequence of good quality for all
six primers was obtained in 85.3% of the samples. Sequences
that were partially single stranded due to failure of one or two
sequencing primers were seen in 12.9 and 1.7% of the samples,
respectively.
For 227 of the 346 patients with an available PR and RT
sequence, including all 90 samples from Cameroon, all 37 sam-
ples from Kenya and 100 of the 219 samples from Belgium,
genotyping was requested to assess the presence of baseline
resistance. Only in 20 of these therapy naive patients, mutations
at one of the positions associated with resistance in either the RT
gene (codons 41, 44, 62, 65, 67, 69, 70, 74, 75, 77, 98, 100, 101,
103, 106, 108, 115, 116, 118, 151, 181, 184, 188, 190, 210, 215
and 219) or the PR gene (codons 30, 32, 33, 46, 48, 50, 53, 54,
73, 82, 84, 88 and 90) were detected (see Table 1). All mutations
were single mutations and none of these isolated mutations on
its own is expected to lead to a reduced response to any HAART
regimen. In one patient however (BE03026) the observation of
a T215D mutation in the RT gene indicated possible infection
with an AZT resistant strain and a subsequent faster evolution
towards resistance when an AZT containing regimen is eventu-
ally initiated.
Sixty-six patients, all sampled in Belgium, were screened
because of therapy failure. Resistance inducing mutations were
detected in 50. A mutation at position 215 of the RT gene was
observed most frequently (24 patients) followed by the M to I
or V substitution at position 184 (21 patients) (see Table 1). All
mutations observed were in accordance with the expectations
based on the current medication and/or the treatment history of
the patient.
3.3. Detection of resistance in patients with low viral loads
Twenty-three of the 140 patients with a viral load below 1000
copies per ml were subjected to genotyping because of indi-
cations of therapy failure. A completely wild type virus was
detected in six, including three patients (BE96031, BE96042
and BE92022) with samples collected during an occasional
blip of the viral load, one patient (BE00041) in whom ther-
apeutic drug monitoring revealed suboptimal lopinavir con-
centration and adaptation of the lopinavir dosage resulted
in a subsequent drop of the viral load below the detection
limits, and one patient (BE01011) suspected of bad therapy
adherence.
Resistance mutations were detected in 18 patients. Twelve of
them had a long history of treatment and treatment failure and the
observed mutational patterns were comparable to the ones from
previous blood drawings or were in accordance with the expecta-
tions based on the treatment history. In six patients (BE135812,
BE99021, BE02061, BE89019, BE02028 and BE04025)
genotyping was performed for a first regimen failure.
The failing HAART regimens were AZT + 3TC + ABC (in
BE02028), 3TC + ddI + TFV (in BE02061 and BE89019),
d4T + 3TC + NFV (in BE135812), AZT + 3TC + NFV (in
BE99021) and AZT + 3TC + LPV (in BE04025). In four patients
(BE02028, BE99021, BE02061 and BE89019) the mutations
were detected within 6 months after starting the treatment. The
RT mutation M184I/V was detected in all six. Additional muta-
tions observed were the RT substitutions K65R (in BE89019)
and M41L (in BE135812) and the PR substitution L90M (in
BE135812).
3.4. Performance of the RT-PCR for different HIV-1
subtypes
Fig. 3 shows a phylogenetic tree based on the RT sequences
of all the patients for whom a sequence was obtained. Different
subtypes reference sequences were included. Ten different sub-
types were represented in the patient’ cohort that was selected
for the evaluation (A, B, C, D, CRF01 AE, F, G, CRF02 AG, H
and J). Representatives of subtypes A, B, C, D, CRF01 AE, F,
G, CRF02 AG, H, K and 06 CPX were also found amongst the
97 samples with viral loads below 500 copies/ml and positive
RT-PCR results (55% subtype B, 12% subtype CRF02 AG, 8%
subtype CRF02 AE, 6% subtype F, 5% subtype C, 4% subtype
A, 4% subtype G, 2% subtype D and 1% subtype K, 1% subtype
H and 1% 06 CPX).
3.5. Manipulations and costs of the procedure
Table 2 gives an overview of all the manipulation steps with
indications concerning hands-on time and cost. Only the cost
of reagents and disposables (current prices in Belgium) is taken
into account in these calculations.
Necessary equipment to perform the test includes a cooled
centrifuge able to run at high-speed, a thermal cycler, equip-
ment to run agarose gels and an instrument for capillary elec-
trophoresis or an automatic sequencer. All manipulations can be
performed in a level 2 laboratory.
4. Discussion
With the improved availability of HAART in resource limited
settings (James, 2001), the demand for accurate but affordable
monitoring of patients under treatment is becoming a prior-
ity (Kent et al., 2003). Indeed, a better access to antiretroviral
drugs without adequate control and monitoring, might result in
widespread transmission of drug resistant virus. An epidemic of
drug-resistant HIV strains in developing countries can only be
prevented by proper measures that guarantee that patients are
prescribed only highly effective drug combinations, promote a
correct intake of the medication, support the uninterrupted sup-
ply of the drugs, ensure the availability of laboratory methods to
monitor side-effects and the success or failure of the treatment,
and provide clear guidelines for actions in case of therapeu-
tic failure. Laboratory methods to monitor success or failure of
therapy must include at least CD4 count and viral load deter-
minations and preferentially detection of drug resistance. The
access to commercial assays for viral load monitoring and for
determination of drug resistance in Africa is still limited due to
the high costs.
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Table 1
List of all patients in whom one or more mutations at codon positions associated with resistance were detected
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Fig. 3. Neighbor-joining tree based on the HIV-1 RT nucleotide sequences of the patients for whom successful amplification and sequencing was performed. (a)
Sequences from samples collected in Europe (Belgium) and (b) sequences from samples collected in Africa (Cameroon and Kenya). The trees were constructed using
the neighbor-joining method included in the Philip package. Numbers at the branch nodes indicate bootstrap values. For patients from whom 2 or 3 samples from
different time points were included in the study, only one sequence was used for the construction of the phylogenetic tree. For sexual contacts known to be infected
with the same virus (donor-recipient pairs) also only one sequence was included for phylogenetic analysis.
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Fig. 3. (Continued ).
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Table 2
Hands-on time and costs of the different steps of the RT-PCR genotyping system
Product Manipulations Hands-on time Cost per analysis (in Euro)
A. Detection of plasma HIV-1 RNA
Plasma Centrifugation 10 min 0.00
↓ RNA extraction 60 min 6.02
Purified RNA RT-PCR 30 min 9.29
↓ Agarose gel electrophoresis 30 min 4.91
RT-PCR amplicon
Subtotal 2 h 10 min 19.50
B. Genotyping of HIV-1 RNA
RT-PCR amplicon Purification 30 min 2.69
↓ Sequencing reaction 20 min 22.79
Sequence amplicon Purification 60 min 1.73
↓ Visualization 30 min 8.15
RT and PR sequence Validation 20 min 0.00
Interpretation 10 min 0.00
Total 4 h 40 min 54.86
In this report an in-house genotyping method with high sensi-
tivity for a large number of different HIV-1 subtypes is described.
Although a well-equipped laboratory is still a necessity, this
technique can be performed for a total reagent cost of 55 Euro,
which is significantly lower than the commercially available
systems. Moreover, the high sensitivity of RT-PCR step of the
procedure, with a detection limit of below 500 copies/ml, permits
its use as a qualitative screening test in patients under treatment.
It also allows to discriminate between those with successful
treatment (no detectable virus in the plasma) and those with
therapy failure (detectable virus in the plasma), reducing the
need for viral load determination. The costs for this qualitative
RT-PCR alone are about 20 Euro with only a centrifuge and
a thermal cycler needed. For the patients with detectable virus,
genotyping of the amplified viral RNA for drug resistance can be
initiated immediately for an additional cost of 35 Euro. The use
of this method in the follow-up of patients under treatment will
allow the fast detection of arising resistance at a more affordable
price than the commercial tests.
It should be stressed that all commercial viral load and geno-
typic resistance assays currently available have been optimized
for genetic subtype B strains while most of the infected patients
worldwide are infected with non-B subtypes. And although at
least the performance of two commercially available sequenc-
ing kits, the HIV Genotyping System kit and the TruGeneTM
HIV kit (Jagodzinski et al., 2003) can be considered as appro-
priate, problems with non-B strains are occasionally reported
(Beddows et al., 2003; Fontaine et al., 2001; Mracna et al., 2001).
Therefore the patient’ cohort for evaluating the in-house method
was specifically selected to embrace viral strains with a broad
genetic diversity. Although subtype B is still the most preva-
lent in Belgium, it is responsible for only less than half of all
the infections (Snoeck et al., 2002,2004). To further enlarge the
non-subtype B group an important number of samples collected
in Western Africa (Cameroon) and some samples collected in
Eastern Africa (Kenya) were included. Several studies have
shown the extensive subtype diversity of HIV-1 strains from
Cameroon with an important representation of the recombinant
form CRF02 AG and of the subtypes G, J and F (Fonjungo et
al., 2002, Nkengasong et al., 1994). In Kenya, subtype A is the
most prevalent, followed by subtypes D, C and G (Neilson et al.,
1999).
The RT-PCR genotyping system proved to be highly success-
ful for the amplification of African strains with positive results
for 127 of the 132 African samples included. The five drop-outs
had undetectable (n = 3) or very low (n = 2) viral loads in the
Amplicor assay.
Commercial genotyping systems do not recommend the use
of their assay for samples with viral loads of less than 1000
copies/ml. This recommendation is based on the fact that the
success rate of the systems in low viral load samples is low and
on the assumption that amplification of low viral load samples
might lead to selection of non-representative strains. The lat-
ter assumption however was never supported by scientific data.
Although the number of tested patients is limited, the results
do indicate that genotyping as soon as therapy failure is sus-
pected, despite extremely low viral loads, can be meaningful. In
four patients resistance against one or two components of the
HAART regimen was detected within 6 months after initiation,
despite the fact that the viral load in these patients at the time
of sampling was still extremely low (respectively 118, 169, 230
and 557 copies/ml). Not surprisingly, the observed resistance
was against the components with the lowest threshold to resis-
tance: 3TC (in all four) and tenofovir (in one).
The main objective of this report was to present an RT-PCR
genotyping system for the monitoring of HIV-infected patients
under treatment. The method described is able to amplify and
sequence HIV-RNA from plasma samples from a random selec-
tion of patients encompassing different subtypes and an impor-
tant number of patients with low viral loads. The method is
therefore suitable for both detection of residual virus replica-
tion in the plasma and detection of drug resistance and can be
performed at a significant lower price than the current commer-
cial viral load and genotyping assays. Although the use of some
expensive instrumentation is necessary, the equipment needed
is versatile and can be used for other PCR and sequencing appli-
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cations. A well equipped laboratory and sufficiently trained
personnel remains however important. Time has come for the
diagnostic industry and for the producers of laboratory equip-
ment to follow the example of the pharmaceutical companies,
which have supplied medication at affordable price for those
countries where HIV is devastating to social and economical
life. Now that therapy has become available, affordable follow-
up of treatment and possible failure should be supplied urgently,
such that therapies can be adopted and the rise of resistance
among the population of viral strains can be kept at a safe level.
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Due to high cost, availability of human immunodeficiency virus type 1 (HIV-1) drug resistance testing in
resource-poor settings is still limited. We therefore evaluated the usefulness of viral DNA extracted from either
whole blood or dried blood spots (DBS). Samples were collected from 50 patients receiving therapy and 10
therapy-naı¨ve patients. Amplification and sequencing of RNA and DNA was performed using an in-house
assay. Protease (PR) and reverse transcriptase (RT) sequences of plasma viral RNA were obtained for 96.6%
and 89.7%, respectively, of the 29 patients with a detectable viral load. For cellular viral DNA, useful PR and
RT sequences were obtained for 96.6% and 93.1% of the whole-blood-cell samples and for 93.1% and 93.1% of
the DBS samples, respectively. For the 31 patients with an undetectable viral load, PR and RT sequences were
obtained for 67.7% and 61.3% of the whole-blood-cell DNA preparations and for 54.8% and 58.1% of the DBS
DNA preparations, respectively. A good correlation between RNA and DNA sequences was found; most
discordances were caused by the detection of mixed amino acids. Of the RT drug-resistant mutations, 13
(38.2%) were seen in RNA only, 6 (17.6%) in DNA only, and 15 (44.1%) in both. Repeated amplification and
sequencing of DNA extracts revealed a lack of reproducibility for the detection of drug resistance mutations in
a number of samples, indicating a possible founder effect. In conclusion, this study shows the feasibility of
genotypic drug resistance testing on whole blood cells or DBS and its possible usefulness for HIV-1 subtyping
or examining the overall distribution of drug resistance in a population. For individual patients, RNA
sequencing was shown to be superior to DNA sequencing, especially for patients who experienced early
treatment failure. The use of DNA extracted from whole blood or DBS for the detection of archived drug
resistance mutations deserves further study.
Today, more than one million people in low- and middle-
income countries have access to antiretroviral treatment
(ART). Even though this is only 23% of the estimated 4.6
million human immunodeficiency virus type 1 (HIV-1)-in-
fected individuals who are in need of highly active ART
(HAART), it proves that the delivery of ART in resource-poor
settings is feasible (41). Experiences from Europe and the
United States, however, indicate that the emergence of HIV
drug resistance remains an important obstacle to the long-term
success of therapy. An adequate follow-up of patients on treat-
ment, in order to identify cases in which therapy has failed, is
essential to avoiding accumulation of drug resistance. Efforts
to lower the prices for CD4 and viral load testing are being
made, and alternative methods for measuring these parame-
ters in resource-poor settings are being developed and evalu-
ated (8, 12, 17). Unfortunately, genotypic resistance testing
remains almost inaccessible due to its high cost, the need for
specialized laboratories, and the logistical challenges, such as
the requirements for a cold chain to transport samples from
the field to reference laboratories. However, ART drug resis-
tance testing in patients in whom treatment is failing remains
very important, not only to guide a second line of treatment for
individuals but also to allow the monitoring of the emergence
and distribution of drug-resistant virus in the population.
In a previous study, we presented a sensitive method for
combined detection of the presence of HIV-1 in plasma and
subsequent sequencing of the protease (PR) and reverse trans-
criptase (RT) genes (36). Although this technique allows a
significant reduction in the price of follow-up testing, the need
for a proper infrastructure for collection and transportation of
blood samples remains.
The aim of the current study was to evaluate the possibility
of using cellular DNA instead of viral RNA for the detection
of drug resistance mutations. As DNA is more stable than
RNA, the use of DNA would eliminate the necessity for fast
processing of the blood samples after collection and reduce the
complexity of the manipulations. The fact that a reverse tran-
scription step is no longer needed for the amplification of the
genes of interest also reduces the overall cost of the procedure.
Blood spots collected on filter paper have been used for DNA
amplification purposes, but reports on the feasibility of per-
forming genotypic analysis for HIV-1 drug resistance remain
scarce (24, 33, 43). In resource-poor settings, dried blood spots
(DBS) are the preferred method of sample collection in the
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field, as they do not require electricity or a cold chain. More-
over, once the samples are air dried on the paper, they can be
handled as noninfectious and transported to the laboratory
without the risk of infection transmission (19).
Whether the same resistance information can be obtained
from DNA sequencing and RNA sequencing is still unclear.
Results of published reports in this regard are very inconsistent
(6, 10, 14, 21, 24, 34). The present study aims to investigate
both the possibility of DNA sequencing from whole blood cells
or from DBS and the usefulness of DNA sequencing for de-
termination of drug resistance in patients from a resource-poor
setting with a high level of HIV-1 subtype diversity.
MATERIALS AND METHODS
Patients and samples. In May 2006, a total of 50 patients on HAART and 10
ART-naı¨ve patients were randomly selected from the HIV Comprehensive Care
Centre at Coast Province General Hospital in Mombasa, Kenya. The patients
were seen during regular follow-up visits, and written informed consent for
participation in the study was obtained. The study was approved by the ethics
review committees of the University of Nairobi and the Ghent University. The
mean age of the patients was 36.9 years (standard deviation, 9.2 cells/mm3;
range, 21 to 65 years), 38 (63%) of the patients were women, and 66% of the
patients were in WHO clinical stage 3 or 4 (42). The mean CD4 count was 322
cells/mm3 (standard deviation, 166 cells/mm3; range, 41 to 757 cells/mm3).
Patients on HAART were treated with the current regimen for a median of 12
months (ranging from 1 week to 33 months). The current regimen of two
nucleoside RT inhibitors (NRTIs) (stavudine [d4T]/zidovudine [AZT] and lami-
vudine [3TC]), and one nonnucleoside RT inhibitor (NNRTI) (nevirapine [NVP]
or efavirenz [EFV]), was the first-line regimen for 48 patients. Two patients
received a second-line protease inhibitor (PI; lopinavir/ritonavir [LPV/r])-based
regimen.
Ten milliliters of EDTA blood was collected, and 50 l of whole blood was
immediately spotted four times on filter paper (Schleicher and Schuell 903).
Filter papers were air dried overnight and stored at20°C until processing. CD4
cell counts were performed (FACScount; Becton Dickinson Immunocytometry,
Oxford, United Kingdom), and the remainder of the EDTA blood was centri-
fuged to collect the plasma and the buffy coat cells. Plasma and whole blood cells
were stored at 80°C and 20°C, respectively. All samples were shipped to the
AIDS Reference Laboratory at the University Hospital in Ghent, Belgium.
RNA viral load testing. HIV RNA quantification was performed using the
ultrasensitive Cobas Amplicor HIV-1 Monitor test, version 1.5 (Roche Molec-
ular Systems, Branchburg, NJ), with a detection limit of 50 copies/ml.
DNA extraction. DNA was extracted from the blood cells by use of the
QIAamp DNA blood mini kit (QIAGEN, Venlo, The Netherlands), following
the instructions of the manufacturer, and eluted in 50 l elution buffer.
The procedure to extract DNA from the DBS was adopted from that of Fisher
et al. (15). Briefly, one whole DBS was cut into small pieces and transferred to
a 2-ml tube. One milliliter of phosphate-buffered saline solution (Cambrex Bio
Science, Verviers, Belgium) with 0.1% Tween 20 (Sigma-Aldrich, Bornem, Bel-
gium) was added. The mixture was subjected to a vortex briefly, and after 10 min
of incubation at room temperature, the supernatant was removed. This wash step
was repeated twice. After the final wash step, 200 l of 5% Chelex-100 resin
solution (Bio-Rad, Nazareth, Belgium) was added and the sample was incubated
for 30 min at 56°C and another 30 min at 95°C. The supernatant was then
transferred to a clean tube and stored at 20°C until processing.
Amplification of RNA and DNA extracts. Amplification of HIV RNA was
performed by nested RT-PCR as previously described (36). DNA extracts from
the blood cells and the DBS were amplified by nested PCR using the same
primer sets as the ones used for RNA amplification. The first round of amplifi-
cation was carried out using 5 U/l of Taq polymerase (Applied Biosystems Inc.,
Foster City, CA) in a 25-l reaction volume containing buffer II (Applied Bio-
systems) with 25 mM MgCl2, 1.25 mM deoxynucleoside triphosphates (Amer-
sham Biosciences, Buckinghamshire, United Kingdom), 0.1% bovine serum al-
bumin (Roche Diagnostics, GmbH Mannheim, Germany), and 0.05 M each of
two forward primers (GAG2 [5-GAGGAAGCTGCAGAATGGG-3] and PR1
[5-ATGATGCAGAGAGGCAATTT-3]) and two reverse primers (RT137 [5-
TTCTGTATGTCATTGACAGTCCAGC-3] and RT3303 [5-TAAYTTYTGT
ATRTCATTGAC-3]). Primers were selected to have a broad specificity for
different HIV-1 subtypes.
Cycling conditions were 94°C for 5 min followed by 35 cycles at 94°C for 30 s,
50°C for 30 s, and 72°C for 2 min and a final extension for 7 min at 72°C.
Two-microliter volumes of the outer RT-PCR products were used in two sepa-
rate inner PCRs, one with nested PR primers (PR3 [5-AGAGCCAACAGCC
CCACCA-3] and PR4 [5-GGGCCATCCATTCCTGGCTT-3]) and one with
nested RT primers (RT1 [5-CCAAAAGTTAAACAATGGCCATTGACAGA-
3] and RT4 [5-AGTTCATAACCCATCCAAAG-3]). The second-round PCR
was carried out using Taq polymerase (Applied Biosystems Inc., Foster City, CA)
in a 50-l reaction volume containing Taq buffer II with 5 U/l of Taq polymer-
ase, 25 mM MgCl2, 1.25 mM deoxynucleoside triphosphates (Amersham Bio-
sciences, Buckinghamshire, United Kingdom), and 0.05 M each of the specific
forward and reverse primers. The second-round PCR included an initial dena-
turation step at 94°C for 5 min followed by 35 cycles at 94°C for 30 s, 50°C for
30 s, and 72°C for 30 s and a final extension for 7 min at 72°C.
In each PCR run, a sample containing 10 copies of HIV-1 DNA (DNA
equivalent of 10 8E5 cells) was included as a positive control. Ultrapure water
was used as a negative control. Results were accepted only if the results of both
controls were correct.
The PR primers amplify a 458-bp fragment spanning the whole PR gene. The
RT primers amplify a 646-bp fragment spanning nucleotides corresponding to
amino acids 27 to 227 of the RT gene. The amplification products were visualized
after electrophoresis in a 1% agarose gel with ethidium bromide.
Genotyping of PR and RT genes. Genotyping was performed using a home-
made sequencing assay as described earlier (36). Direct sequencing of both sense
and antisense strands was done with the dRhodamine Terminator Cycle Se-
quencing Ready Reaction kit (Applied Biosystems Inc., Foster City, CA). Se-
quencing reaction products were analyzed on an ABI310 or ABI3130XL genetic
analyzer (Applied Biosystems Inc.). All validations and subsequent manipula-
tions of the sequencing results, as well as the interpretations of the genotyping
data and the subtyping, were performed using the Smartgene HIV software
packages (Integrated Database Network System; Smartgene, Zug, Switzerland).
The selection of drug resistance mutations was based on the Stanford algorithm
(http://hivdb.stanford.edu).
Phylogenetic analyses. Phylogenetic analyses were performed using version
3.6 of the PHYLIP package (http://evolution.genetics.washington.edu/phylip
.html) with a maximum-likelihood distance matrix and a transition-to-trans-
version ratio of 2.0. Tree diagrams were plotted with Treeview, version 1.4
(included in the PHYLIP package). Nucleotide differences were calculated
using the Emboss infoalign software (http://embossgui.sourceforge.net/demo
/infoalign.html).
Statistical analysis. All statistical analyses were performed using SPSS 15.0
(SPSS, IL). Pearson’s chi-square test was used to detect possible statistically
significant differences between two groups of samples.
RESULTS
Viral load determination and RNA sequencing. A detectable
viral load (50 copies/ml) was found in all 10 treatment-naive
patients (mean, 35,555 copies/ml; range, 73 to 100,000 cop-
ies/ml) and in 19 of the 50 treated patients (mean, 20,377
copies/ml; range, 55 to 100,000 copies/ml).
Sequencing of the viral RNA was attempted on all 29 of
these samples and was successful for PR in 28 (96.6%) and for
RT in 26 (89.7%). The three patients for whom one or both
failed had very low viral loads (73, 74, and 81 copies/ml, re-
spectively). The viral load was undetectable in 31 patients, all
treated.
Efficiency of DNA sequencing on whole blood cells and DBS.
Sequencing of the PR and RT genes from whole-blood-cell
DNA was successful for 28 (96.6%) and 27 (93.1%), of the 29
blood-cell samples collected from patients with a detectable
viral load, respectively, and for 21 (67.7%) and 19 (61.3%) of
the 31 samples from patients with an undetectable viral load,
respectively. For the DBS, the success rate was slightly lower,
with 27 (93.1%) successful sequencing reactions for both PR
and RT from the patients with a detectable viral load and 17
(54.8%) PR and 18 (58.1%) RT sequences from the patients
with undetectable viral load. No statistically significant differ-
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ence between the efficiency of genotyping on whole blood
DNA and the efficiency of genotyping on DBS DNA was found
(P values of 0.2743 for PR and 0.8311 for RT [Pearson’s 2
test]).
Subtype distribution. For the 56 patients from whom PR
and RT sequences were available, from DNA, RNA, or both,
subtyping of the HIV-1 strains was performed by similarity
search using the Smartgene subtyping tool. Results showed
that the majority of patients was infected with a subtype A
virus (n  31); in order of prevalence, subtype A was followed
by subtypes D (n  7), CRF16_AD (n  7), C (n  6), and G
(n  1). Discordances between the subtype determined from
FIG. 1. A phylogenetic tree was constructed based on 100 PR and RT gene sequences from 38 patients. Reference strains for subtypes A, C,
D, and CRF16_AD were included in the phylogenetic analysis. The tree was rooted with a subtype B strain. BC, blood cells.
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the PR sequence and the subtype determined from the RT
sequence were seen for four patients (PR/RT subtype combi-
nations D/C, A/C, CRF_AE/C, and C/A). The results of the
subtype determination were not influenced by the sample type.
Comparison of the nucleotide sequences from whole-blood
DNA, DBS DNA, and plasma RNA. A phylogenetic tree was
constructed using 100 PR and RT gene sequences from 38
patients (Fig. 1). The tree revealed a close clustering of the
DNA and RNA sequences from the same patients in all cases.
The mean nucleotide difference, expressed as the percentage
of the total nucleotide length (857 bp), between paired DNA
sequences of blood cells and DBS was 2.10% (range, 0.35% to
4.00%). The mean nucleotide difference between the se-
quences obtained from plasma RNA and blood-cell DNA and
the mean nucleotide difference between the sequences ob-
tained from plasma RNA and DBS DNA were 1.82% (range,
0.35% to 3.73%) and 1.90% (range, 0.58% to 3.50%), respec-
tively. Mixtures of nucleotides (International Union of Pure
and Applied Chemistry nomenclature) were considered differ-
ences. For comparison, the observed mean nucleotide differ-
ences between duplicate sequencing reactions on RNA and
DNA were 1.45% (range, 0% to 3.37%) and 1.61% (range, 0%
to 3.61%), respectively.
Drug resistance mutations in RNA and DNA. Selection of
drug resistance mutations was based on the recent update of
the International AIDS Society-USA list (20). Only two pa-
tients showed primary mutations in the PR gene (correspond-
ing to L33F and D30N).
The mutation resulting in L33F was detected consistently in
all three samples from the same treatment-naı¨ve patient
(BV021). The mutation resulting in D30N was detected as part
of a mixed population in one of the DNA sequences of patient
BV011 (Table 1).
Secondary PR mutations were observed in samples from all
patients. Most of these mutations (74 of the 83) were consis-
tently detected in the RNA and in both of the DNA sequences,
eight mutations were detected in DNA only, and one mutation
was detected in RNA only.
No LPV-related PI resistance-associated mutations were ob-
served in the two patients on a PI-based regimen (BV114 and
BV120) (Table 1).
No NRTI or NNRTI resistance-associated mutations were
observed in samples from the 10 treatment-naı¨ve patients. For
the 43 of 50 treated patients for whom at least one RT se-
quence (RNA and/or DNA) was available, NRTI or NNRTI
resistance-associated mutations were detected in 13 samples
(Table 2). A total of 34 nucleotide substitutions were seen; 10
of these were detected consistently in the RNA and in both
DNA sequences, 5 were detected in the RNA and in one of the
DNA sequences, 3 were detected only in the DNA from blood
cells, and 2 were detected only in the DBS DNA (Table 2).
Thirteen mutations were found exclusively in the RNA. Six
mutations were detected in one or both of the DNA sequences
but not in the RNA. A mutation resulting in a replacement
with residue 103N was seen in the DNA sequence of two
patients on an NNRTI-based regimen but with an undetect-
able viral load.
The number of resistance mutations detected in the DNA
samples of five treated patients with a viral load below 5,000
copies/ml (n  4) was clearly lower than the number of resis-
tance mutations detected in the DNA samples of six treated
patients with a viral load of more than 5,000 copies/ml (n 
17), but the difference did not reach statistical significance
(Pearson’s chi-square P  0.11). The numbers of resistance
mutations in the RNA in both groups, on the other hand, were
comparable, with 12 and 16 mutations found in the RNA from
patients with a viral load below 5,000 copies/ml and from
patients with a viral load above 5,000 copies/ml (Pearson’s
chi-square P  0.83), respectively.
Reproducibility of the DNA sequencing. Replicate amplifi-
cation and sequencing reactions were performed on the DNA
extracts of all individuals listed in Table 2, with the exception
of one ART-naı¨ve patient. The results showed the inconsistent
detection of some mutations (Table 3). Five resistance muta-
tions that originally were not detected in the DNA but were
present in the RNA sample were picked up in at least one of
the replicate DNA-sequencing reactions. However, despite
replicate analysis, several important resistance mutations re-
mained undetectable even after triplicate sequencing of the
DNA: mutations resulting in the presence of 103N and 184V in
patient BV141, mutations resulting in the presence of 103N
and 184V in patient BV123, mutations resulting in the pres-
ence of 67N and 184V in patient BV113, and a mutation
resulting in the presence of 65R in patient BV106.
Replicate sequencing confirmed the presence of the muta-
tion resulting in the presence of 103N in the two patients with
an undetectable viral load while on an NNRTI-based HAART
regimen. The mutation resulting in the presence of 103N was
consistently detected in all replicates of patient BV117 and in
half of the replicates from patient BV112 (Table 3).
Reproducibility of the RNA-sequencing reactions. To eval-
uate the influence of sampling on RNA sequencing, replicate
reactions were performed on four RNA samples (from patients
BV113, BV123, BV132, and BV141). Results were much more
consistent than those for DNA. In samples from patients
BV123 and BV141, the same resistance mutations were de-
tected in all reactions. For patient BV113, the mutation result-
ing in a D67N substitution was detected in only two of the four
replicates. For patient BV132, the mutation resulting in a
K103N substitution was detected in only two of the five repli-
cates (results not shown).
DISCUSSION
In the last 25 years, DBS have been used for various pur-
poses, including detection of HIV antibodies (2, 5, 18, 23, 31),
detection of HIV antigen (22, 32), early diagnosis of perina-
tally infected infants (4, 15, 28, 30, 35), quantification of CD4
T cells (26), and quantification of viral plasma RNA (1, 3, 7, 9,
16, 25, 29). Few studies examined the possibilities of perform-
ing drug resistance testing on dried blood, plasma, or serum on
filter paper (24, 33, 43). Because of the ease to collect, store,
and transport DBS, use of DBS is the ideal method for blood
sampling in resource-poor rural settings. This, combined with
the possibility of directly amplifying the genes of interest, with-
out the need for a reverse transcription step, therebyreducing
both complexity and cost of genotyping procedures (price re-
duction of 12 U.S. dollars/test), is an important advantage in
view of efforts to increase the accessibility of resistance testing
in resource-poor regions.
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TABLE 1. Overview of all patients with mutations at resistance-related positions in the PR gene
Patient ART (length of treatment) VL(copies/ml)a
CD4
(cells/mm3) Sample
b
Residue encoded in place of indicated amino acid
10L 13I 16G 20K 30D 33L 36M 46M 63L 71A 73G 77V
BV021 None 73 474 DBS V E F I/T I
BC V E/G F T I/V
RNA V E F T I
BV016 None 5,330 233 DBS V E I
BC V E I
RNA V E I
BV010 None 9,790 702 DBS V/L I
BC V I
RNA V I
BV011 None 16,900 390 DBS V V I T
BC V V N/D I
RNA V V I
BV028 None 21,600 473 DBS I/V I
BC V I
RNA V I
BV018 None 35,400 246 DBS I V I I/M S
BC I V I
RNA I V I
BV030 None 66,300 109 DBS I
BC I
RNA I
BV002 None 100,000 136 DBS V E I I
BC V E I I
RNA V E I I
BV020 None 100,000 165 DBS I/V V I P/L
BC I/V V I L/V
RNA I/V V I L/V
BV107 d4T  3TC  EFV (6 mo) 55 338 DBS V E R I T
BC V E R I T
RNA V E R I T
BV120 AZT  3TC  NVP (41 mo), 81 226 DBS I P
d4T  3TC  LPV/r (9 mo) BC I P
RNA I P
BV142 AZT  3TC  NVP (2 mo) 128 236 DBS V R I P/L
BC V R I
RNA V R I
BV145 d4T  3TC  EFV (33 mo) 294 206 DBS V I
BC V I
RNA V I
BV113 d4T  3TC  EFV (32 mo) 1,030 467 DBS V V E I
BC I V E I
RNA V V E I
BV102 d4T  3TC  NVP (1 wk) 1,250 111 DBS V V I
BC V/L V I
RNA V V I
BV127 d4T  3TC  EFV (3 mo) 1,690 314 DBS V I
BC V I
RNA V I
BV132 d4T  3TC  EFV (2 wk) 2,260 41 DBS R I
BC R I
RNA I/V R I
BV144 d4T  3TC  NVP (2 mo) 2,520 182 DBS I
BC I
RNA I
BV123 d4T  3TC  NVP (8 mo) 3,060 321 DBS V I P
BC V R I
RNA V R I
BV106 d4T  3TC  NVP (23 mo) 3,520 300 DBS V I P
BC V I P
RNA V I P
BV141 d4T  3TC  NVP (13 mo) 10,400 388 DBS I
BC I
RNA I
BV114 d4T  3TC  EFV (34 mo), 15,300 217 DBS V E R I
AZT  3TC  LPV/r (1 mo) BC V E R I
RNA V E R I
BV105 AZT  3TC  EFV (9 mo) 21,000 276 DBS I P
BC I/M P
RNA I P
BV139 d4T  3TC  EFV (1 wk) 26,300 556 DBS V I
BC V I
RNA V I
BV147 d4T  3TCEFV (13 mo) 98,200 218 DBS V E I
BC I V E I
RNA I/L V E I
BV116 d4T  3TC  NVP (22 mo) 100,000 353 DBS V V R I
BC V V R I
RNA V V R T
BV133 d4T  3TCNVP (8 mo) 100,000 165 DBS NDc ND ND ND
BC I/V V E I
RNA V V E I
a VL, viral load.
b RNA, plasma RNA; BC, blood-cell DNA; DBS, dried blood spot DNA.
c NA, not applicable.
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TABLE 3. Results of replicate amplification and sequencing reactions performed on DNA extracts
Patient
ART (length of
treatment)
VL
(copies/ml)a
CD4
(cells/mm3)
Sampleb
Residue encoded in place of indicated amino acid
65K 67D 69T 70K 75V 101K 103K 108V 151Q 181Y 184M 188Y 190G 215T 219K 225P
BV145 d4T  3TC  EFV 294 206 DBS1 N
(33 mo) DBS2 N/K
DBS3 N/K M/V
BC1 N
BC2 N V
BC3 N
RNA N I V
BV113 d4T  3TC  EFV 1,030 467 DBS1
(32 mo) DBS2
DBS3
BC1
BC2
BC3
RNA N V
BV132 d4T  3TC  EFV 2,260 41 DBS1 N
(2 wk) DBS2 N C
DBS3 R C
BC1 R C
BC2 R C
BC3 N C
RNA N/T K/N C/Y
BV123 d4T  3TC  NVP 3,060 321 DBS1
(8 mo) DBS2
DBS3
BC1
BC2 K/R
BC3
RNA N V
BV106 d4T  3TC  NVP 3,520 300 DBS1
(23 mo) DBS2 V
DBS3 H/D
BC1
BC2
BC3
RNA R/K V
BV141 d4T  3TC  NVP 10,400 388 DBS1
(13 mo) DBS2
DBS3
BC1
BC2
BC3
RNA N V
BV114 d4T  3TC  EFV 15,300 217 DBS1
(34 mo), AZT  DBS2 N I/V
3TC  LPV/r DBS3 N A/G
(1 mo) BC1 K/N
BC2 K/N T/A
BC3 N A H
RNA N H
BV105 AZT  3TC  EFV 21,000 276 DBS1 N V
(9 mo) DBS2 N I V
DBS3
BC1 N/K V/M
BC2 N I/V V
BC3 N I/V V/M
RNA N V
BV147 d4T  3TC  EFV 98,200 218 DBS1 I/V K/N I/V K/E
(13 mo) DBS2 N
DBS3
BC1 I/V N M/V H/P
BC2 N V F H
BC3 D N H
RNA N V F
BV116 d4T  3TC  NVP 100,000 353 DBS1 R N V
(22 mo) DBS2 I/V N I/V V
DBS3 N V
BC1 N V
BC2 N V
BC3 N V
RNA N V
BV133 d4T  3TC  NVP 100,000 165 DBS1 N M/Q/K/L V L A
(8 mo) DBS2 K/E V L A
DBS3
BC1 N/T M/V L A
BC2 V L/F A
BC3 N M V L A
RNA N/T M V L A
Continued on facing page
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The results of the study presented confirmed the feasibility
of extracting and subsequently sequencing HIV-1 DNA from
DBS as shown by others (24, 43). The sensitivity of our in-
house genotyping assay for sequencing DNA from DBS was
only slightly lower than the sensitivity for sequencing DNA
extracted from whole blood cells. Besides allowing the success-
ful sequencing of the PR and RT gene in 93.1% of the patients
with a detectable viral load, the DBS also allowed PR and RT
gene sequencing of samples from more than 50% of the pa-
tients with an undetectable viral load. The reduced sensitivity
compared to that of the patients with a detectable viral load
suggests a correlation between the viral DNA contributions in
DBS and the plasma viral load, as was reported by McNulty et
al. (24). Although one might expect that in patients with a low
CD4 count, the total number of HIV-infected cells per volume
of blood is limited, no relation was seen between low CD4
counts and failure to amplify viral DNA from DBS or failure to
detect resistant strains in the DNA (results not shown). The
possibility of obtaining sequence information from patients
with an undetectable viral load can be valuable for epidemio-
logical studies and subtype determination and might allow the
detection of mutations selected during previous suboptimal
treatment regimens, as is discussed below.
If all nucleotides are considered, irrespective of the impor-
tance of their position for drug resistance, good correlations
between the nucleotide sequences of DBS DNA, whole-blood-
cell DNA, and RNA were obtained, with differences that only
slightly exceeded the differences observed between replicate
sequencing reactions starting from the same DNA or RNA
extract. For the detection of mutations at positions associated
with drug resistance, however, superiority of RNA sequencing
over DNA sequencing was observed. Relying on only the DNA
sequence would lead to a misinterpretation of the assumed
phenotypic resistance in 6 of the 11 patients with significant
resistance in the virus in the plasma, irrespective of whether
blood cells or DBS sequences were considered.
The feasibility of using viral DNA for the establishment of
drug resistance is still controversial. Some studies reported
more mutations in the plasma RNA (6, 10, 21, 24), and others
reported more mutations in the cellular DNA (14, 34). Most of
these discordances may be attributed to differences in the
selection of the samples used for the evaluation. While plasma
RNA represents the population of short-lived actively replicat-
ing virus, viral DNA from infected cells is composed of a
heterogeneous mix of DNA from acutely infected, actively
virus-producing cells as well as quiescent cells that form the
viral reservoir (13, 27, 40). Due to the limited capacities of
current population-based sequencing genotyping methods, mi-
nor variants can remain undetectable (38). The virus replicat-
ing in plasma in the early stage of resistance development most
probably derives from a small number of cells in the reservoir,
and therefore, detection of resistant virus in plasma will pre-
cede detection in the cells. Since all patients in this study
initiated HAART very recently and about half of the 11 pa-
tients in whom drug resistance mutations were detected still
had a viral load of less than 5,000 copies/ml at the time of
sampling, they can be considered early treatment failures. Al-
though the number of patients is limited, a correlation between
low viral load and a reduced capacity for the detection of
resistance mutations in DNA compared to that of resistance
mutations in RNA was observed, further strengthening the
hypothesis of a relationship between duration of treatment
failure and the ability to detect drug resistance in DNA, as was
suggested by Bi et al. (6).
Despite a lack of sensitivity in the early phase of treatment
failure, sequencing of viral DNA can be valuable, especially for
patients with previous episodes of treatment failure that were
not documented by resistance analysis. Interruption of a failing
regimen or a failing drug will result in an overgrowth of the
drug-resistant variant by the more fit wild type (13, 27, 40). In
the cellular reservoir on the other hand, the resistant strains
will remain detectable for longer time. Venturi et al. (39)
demonstrated the kinetics of resistant and wild-type virus in
the RNA and DNA compartment very clearly. They found
more mutations in the RNA samples than in the DNA samples
in the patients on a failing treatment, while those undergoing
treatment interruption showed more mutations in the DNA
samples. The same higher level of sensitivity of DNA for the
detection of drug resistance mutations in a group of patients
undergoing treatment interruption was reported by Devereux
et al. (14). Previous exposure to EFV explains the mutation
resulting in the presence of 190A that was found in the DNA
but not in the RNA of patient BV114 one month after a switch
from EFV to LPV. All the other patients that were selected for
TABLE 3—Continued
Patient
ART (length of
treatment)
VL
(copies/ml)a
CD4
(cells/mm3)
Sampleb
Residue encoded in place of indicated amino acid
65K 67D 69T 70K 75V 101K 103K 108V 151Q 181Y 184M 188Y 190G 215T 219K 225P
BV112 AZT  3TC  NVP 	50 242 DBS1 K
(1 mo) DBS2 K/N
DBS3 K
BC1 K/N
BC2 K
BC3 K/N
RNA
BV117 d4T  3TC  NVP 	50 328 DBS1 K/N
(21 mo) DBS2 N
DBS3 N
BC1 K/N
BC2 N
BC3 N
RNA
a VL, viral load.
b DBS1 to DBS3, DBS samples 1 to 3, respectively; BC1 to BC3, blood-cell DNA samples 1 to 3, respectively; RNA, plasma RNA.
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this study were assumed to be on their first line of HAART.
Nevertheless, programs aimed at evaluating the influence of a
short course of NVP or AZT on mother-to-child HIV-1 trans-
mission have run in this region. Previous exposure to NVP
therefore seems the most plausible explanation for the ob-
served 103N mutation in the DNA of patient BV112. This,
however, cannot explain the resistance pattern for BV117, a
male patient. Surprisingly, both patients BV112 and BV117
showed undetectable viral loads while on NVP-based HAART.
The possibility of obtaining an undetectable viral load with an
NNRTI-based regimen despite the presence of the mutation
resulting in K103N has been observed before (11).
The mutation resulting in the presence of 65R seen in sam-
ples from patients BV106 and BV132 is typically known as a
tenofovir-associated mutation, but its selection by d4T, espe-
cially in patients infected with non-B subtypes, has been re-
ported (37). For patient BV132, the 65R variant was seen in
one of the DNA samples only. From the sequencing results for
the plasma RNA isolated from this patient, it appears that a
mixture of wild-type and mutant strains is present, and this may
be the cause for the mutation resulting in the presence of 65R
to be missed. The other NRTI or NNRTI resistance-associated
mutations that were detected in the DNA sequences only
(those resulting in the presence of 70R, 75I, 108I, 219E, and
225H) are considered to have only a minor impact on the drug
resistance (http://hivdb.stanford.edu).
The finding of PI-associated mutations in the DNA of two
patients who were not on a PI regimen was unexpected. Al-
though the occurrence of 33F in the absence of other PI re-
sistance mutations is rare, we assume that its presence in an
isolate from patient BV021 is due to a natural polymorphism.
The mutations resulting in the presence of 30N and 46I are
seen as part of a mixed population in one of the DNA se-
quences of patient BV011. We cannot exclude the possibility
that this was due to sequencing errors.
The discordances seen between the replicate DNA amplifi-
cation and sequencing reactions indicate that DNA genotyp-
ing, especially genotyping performed on DNA preparations
containing small amounts of viral DNA, is prone to a founder
effect.
In conclusion, the results of this study demonstrate that
whole-blood DNA or DBS DNA sequencing can be a very
useful tool for epidemiological studies aimed at analyzing the
HIV subtype distribution or the overall distribution of drug
resistance mutations in a population. For the follow-up of
individual patients, on the other hand, replacement of RNA
sequencing by DNA sequencing cannot be recommended, due
to the high number of missed mutations, especially in the early
phase of treatment failure. The use of DNA and DBS sequenc-
ing for the detection of drug resistance mutations selected
during previous drug exposure deserves further study.
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Abstract 
 
Objectives: To evaluate treatment success and drug resistance after short term 
antiretroviral therapy (ART) guided by clinical parameters and CD4 count only, in the 
Comprehensive HIV Care Centre (CCC) of Coast Province General Hospital, 
Mombasa, Kenya. 
Methods: 150 patients receiving ART were randomly selected. After determination of 
the plasma viral load, patients with detectable viral load levels were subjected to 
genotypic drug resistance testing. 
Results: At the time of sampling, 132 of the 150 individuals were on ART for more 
than 6 months (median 21 months, IQR: 12 – 26). An efficient viral load reduction to 
below 50 copies/ml was observed in 113 (85.6%) of them. Of the 19 patients with a 
detectable viral load, sequencing of the protease (PR) and reverse transcriptase (RT) 
gene was successful in 16. Major PR mutations were absent but mutations 
associated with drug resistance in RT were detected in 14 of the 16 patients (87.5%). 
High level resistance against at least 2 components of the ART regimen was 
observed in 9/14 (64.3%). The 3TC mutation M184V and the NNRTI mutation K103N 
were most frequent but also the multi-drug resistance Q151M and the broad NRTI 
cross-resistance K65R were observed. 
Conclusion: The results of this study revealed a high success rate of short term ART 
in patients treated in a CCC in a resource-limited setting. Nevertheless, the observed 
high risk of accumulation of resistance mutations at treatment failure and the 
selection of multi-drug resistance mutations in some patients is of great concern.  
 
Keywords: HIV-1, antiretroviral treatment, viral load, resistance, resource-limited 
settings 
 69
Introduction 
Recent data show an HIV prevalence in Kenya of slightly higher than 5% [1], 
resulting in about 1 million Kenyans living with HIV today. The number of individuals 
on antiretroviral therapy (ART) has increased from 3 000 in 2002 to 54 000 in 2005, 
representing about 20% of those in need of treatment [2]. Comprehensive HIV care, 
including counselling, prevention and treatment of opportunistic infections, as well as 
provision of antiretroviral drugs, is currently available in the national referral hospital, 
in 8 provincial hospitals and in 70 district hospitals across the country [2]. The 
country’s goal is to reach 75% of people in need of ART by 2010.  
At the Comprehensive HIV Care Centre (CCC) in Mombasa, decision on when to 
start or switch treatment is based on clinical and immunological parameters (CD4 
count and total lymphocyte count) [3, 4]. Reports on the efficacy of treatment, guided 
by clinical parameters and CD4 count, as well as on the occurrence of drug 
resistance in these settings, are scarce. The aim of this study was to assess, in a 
cross-sectional survey, the rate of viral suppression and drug resistance in a number 
of randomly selected individuals on ART. 
 
Materials and Methods 
Patients and samples 
The CCC at Coast Province General Hospital, Mombasa, Kenya, has been 
operational since 2003. Currently, about 7 000 HIV seropositive patients are 
registered, among whom nearly 3 000 are receiving ART. The patients are regularly 
seen by the CCC staff and receive the standard of care following the Kenyan 
National Guidelines for antiretroviral drug therapy [3]. ART treated patients attending 
the CCC between 20 April 2006 and 27 April 2006 and between 8 May 2007 and 18 
May 2007 were consecutively asked to participate in this surveillance study. A total of 
150 patients were included. After obtaining informed consent, basic demographical 
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and clinical data was obtained from each patient. Adherence was measured by self 
report and pill count recorded as satisfactory (>95%) or unsatisfactory (<95%). Ten 
ml of EDTA blood was collected for CD4 cell count (FACScount Becton & Dickinson 
Immunocytometry, Oxford, UK). The remainder of the EDTA blood was centrifuged to 
collect plasma which was stored at -80°C until processing for viral load measurement 
and sequencing.  
 
Roche Amplicor HIV-1 Monitor 1.5 Assay 
Plasma HIV RNA quantification was performed, using the Ultrasensitive Cobas 
Amplicor HIV-1 Monitor Test version 1.5 (Roche Diagnostics, Basel, Switzerland) 
with a lower detection limit of 50 copies/ml. 
 
Amplification and genotyping of PR and RT genes 
Extraction, amplification and genotyping of HIV RNA was performed by nested RT-
PCR and a home-made sequencing assay as previously described [5]. All validations 
and subsequent manipulations of the sequencing results, as well as the 
interpretations of the genotyping data and the subtyping were performed using the 
SmartgeneTM HIV software packages (Integrated Database Network System, 
Smartgene, Zug, Switzerland). Selection of drug resistance mutations was based on 
the recent update of the IAS-USA list [6]. 
 
Statistical analysis 
All statistical analyses were performed using SPSS 15.0 (SPSS, Illinois, USA). 
 
Results 
Baseline characteristics of the patients 
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The median age of the participants was 37 years (IQR: 32 - 43) with 69.3% being 
women. The majority (66.7%) of participants were in WHO clinical stage 3 or 4 [7]. 
Baseline CD4 counts were available for 146 participants with a median of 112 
cells/mm³ (IQR: 63 – 184). A combination of d4T+3TC+NVP was the most commonly 
prescribed first line regimen (n=79), followed by d4T+3TC+EFV (n=63), 
AZT+3TC+NVP (n=5), AZT+3TC+EFV (n=2), and d4T+ddI+EFV (n=1). Patients 
receiving their first ART regimen had been treated for a median of 17 months (IQR: 
10 – 24). In 16 patients  treatment was changed after a median of 18 months (IQR: 
13 - 26) by switching one (n=7), two (n=5) or three (n=4) drugs because of adverse 
events including lipodystrophy and/or peripheral neuropathy (n=8), start of anti-
tuberculosis treatment (n=1), unavailability of drugs (n=1), or immunological failure 
(n=6). 
 
HIV RNA viral load quantification, CD4 count and adherence 
Eighteen of the 150 patients initiated ART less than 6 months (median 3.5 months, 
IQR: 2 – 6) before blood collection. The viral load was detectable in 8/18 with a 
maximum value of 26 300 copies/ml. These patients were excluded for further 
analyses. 
For the 132 patients on ART for more than 6 months, an undetectable viral load was 
seen in 110 (87.3%) of the 126 patients without treatment changes or with treatment 
changes for other reasons than immunological failure; and in 3 of the 6 patients who 
had a treatment switch because of immunological failure. The median viral load of the 
19 patients with ongoing viral replication was 3 060 copies/ml (IQR: 294 – 21 000). 
A detectable viral load was not significantly associated with the mean duration of 
ART (P=0.420) or mean baseline CD4 (P=0.177). 
Results of CD4 counts performed on the samples taken for this study were available 
for all 132 patients. A significantly higher mean CD4 count was seen in those patients 
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with an undetectable viral load (n=113, mean=344 cells/mm³) compared to those with 
a detectable viral load (n=19, mean=253 cells/mm³) (P=0.032). However, the mean 
increase in CD4 from baseline level was not significantly different between the two 
groups (P=0.329). 
Seventy-four patients (58.6%) reported to have good adherence (>95%). Good 
adherence was significantly associated with treatment success (P=0.020). 
 
Genotypic resistance  
Sequencing of the viral RNA was attempted on all 19 samples with a detectable viral 
load and was successful for PR in 17 (89.5%) and for RT in 16 (84.2%). Amplification 
failed in 3 patients, all with a very low viral load (79, 81 and 115 copies/ml, after 
respectively 30, 41 and 10 months of treatment). The subtype distribution for these 
17 samples was as follows: subtype A (n=11), subtype C (n=2), CRF16_AD (n=2), 
subtype D (n=1) and an undefined recombinant in one patient. 
No major PR resistance mutations were seen in any of the sequences, but a mean of 
4 minor PR mutations were observed per sample (data not shown). Resistance 
mutations in RT were detected in 14 out of the 16 patients. Overall, the M184V was 
the most commonly observed mutation (n=12), followed by K103N (n=9). In one 
patient the multi-drug resistant Q151M mutation was seen and two patients carried 
virus with a K65R mutation (table 1). In 10 patients a combination of the M184V and 
at least one mutation conferring NNRTI class resistance was observed.  
The two patients who presented with a wild type virus had a viral load of 533 and 
1380 copies/ml after 23 and 26 months of treatment respectively. 
 
Discussion 
The intensive campaign of WHO to improve the availability of ART worldwide is 
gradually beginning to pay off and most African countries are currently able to 
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provide first line ART regimens to a considerable number of HIV-1 infected 
individuals who need medication. Efforts to scale-up laboratory facilities for 
monitoring treatment in these patients however are running behind. A random sample 
survey is often the only way to assess treatment efficacy and the selection of drug 
resistance in comprehensive care treatment programs in Africa. The information 
obtained from these surveys is of high importance for the eventual future adaptation 
of treatment strategies. Moreover, resistance data obtained from these surveys will 
be crucial in evaluating the value of second line treatment regimens in Africa where 
still only a limited number of drugs are available today. 
We sampled 150 individuals receiving ART and found a relatively high percentage 
(82.0%) of complete viral suppression (VL<50 copies/ml), with 85.6% of 132 patients 
treated for more than 6 months having an undetectable viral load. These figures are 
even higher than the ones obtained with similar regimens in the US and Europe [8-
12], but comparable to what has been published for other African regions [13-16]. 
Only Spacek et al. reported a considerable lower rate of viral suppression (66%) in 
Uganda, but in their study patients had to pay for their medication, which might have 
negatively influenced drug adherence [17]. Indeed, a meta-analysis has confirmed a 
higher success rate of virological suppression when free medication is provided [18]. 
The high treatment success rate seen in this study might be partly due to a bias 
because of a possible selection of patients who attend the CCC more regularly. 
These patients could be the more motivated individuals having a better treatment 
adherence. Although the total number of patients was small, a significant correlation 
between adherence and treatment success was demonstrated. 
Despite the high efficacy of the treatment, an exceptional high percentage of the 
patients that were found with a detectable viral load after more than 6 months of 
treatment, presented with drug resistance mutations.  
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The combinations of AZT or d4T with 3TC and EFV or NVP are extensively used as a 
first line regimen in resource-limited settings [19]. Both 3TC and the NNRTIs EFV 
and NVP have a low genetic barrier towards resistance and it is therefore not 
unexpected that, in accordance with the results of other studies, the 3TC mutation 
M184V and the NNRTI mutations K103N, G190A and Y181C are frequently observed 
in case of treatment failure [10, 14]. The high percentage (62.5%) of patients with a 
combination of M184V mutations and at least one NNRTI resistance associated 
mutation, as well as the selection of the broad NRTI cross-resistance mutations 
Q151M and K65R in 3 patients are worrying.  Despite the presence of the thymidine 
analogues AZT or d4T in most of the regimens, thymidine analogue mutations 
(TAMs) were infrequently observed. 
Accumulation of mutations against drugs from different drug classes and/or the 
presence of broad cross-resistance mutations will jeopardize the effectiveness of 
recommended second line regimens that often include ABC and TDF. Moreover, the 
limited availability and the high cost of second line antiretrovirals force clinicians in 
resource-limited settings to recycle drugs. Based on the resistance data from this 
study, we can assume that the effect of second line regimens with recycled drugs will 
be at the most temporary. 
The small number of patients on a second line regimen that were included and the 
limited time period between initiation of this regimen and the date of sampling, did not 
allow us to make conclusions about the efficiency of second line regimens.  
In conclusion, the results of this observational study show that effective first line ART 
treatment in clinical care centres with limited resources is feasible. However, the 
resistance data presented point out the danger of the currently recommended first 
line regimens, when used in the absence of virological monitoring, with regard to the 
accumulation of resistance mutations. The observed high percentage of genotypic 
drug resistance against at least two drugs, questions the usefulness of a second line 
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treatment considering the lack of choice for drugs and the absence of guidance by 
resistance testing. 
Besides high quality adherence counselling, efforts to guarantee a robust supply of 
several antiretroviral drugs from different classes and the worldwide availability of 
affordable and simple viral load and genotyping assays are needed to prevent the 
current success of global ART programs from being only temporary. 
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Table 1:  Overview of the resistance mutations detected in the RT gene of patients with a detectable viral load after more than 6 
months of ART. 
  ART: antiretroviral therapy, VL: viral load, c/ml: copies/ml 
 
 
Sample ID Subtype ART Time
VL  
(c/ml) 
CD4  
(cells/mm³) 65K 67D 69T 75V 103K 108V 151Q 181Y 184M 188Y 190G 215T 225P
BV123 A1+D d4T+3TC+NVP 8m 3060 321       N      V       
BV105 C  AZT+3TC+EFV 9m 21000 276       N      V       
BV275 - d4T+3TC+NVP 10m 115 212 Sequencing not successful 
BV133 A1 d4T+3TC+NVP 10m >100000 165          M   V L A    
BV264 A1 d4T+3TC+NVP 12m 78600 180 R    I     C V   A    
BV141 A1 d4T+3TC+NVP 13m 10400 388       N       V       
BV147 CRF16_AD d4T+3TC+EFV 13m 98200 218       N      V    F H 
BV116 A1 d4T+3TC+NVP 22m >100000 353       N      V       
BV209 A1 d4T+3TC+EFV 23m 533 160                    
BV106 A1 d4T+3TC+NVP 23m 3520 300 R            V       
BV255 A1 d4T+3TC+NVP 26m 1380 83                    
BV232 D  d4T+3TC+NVP 26m 10100 149       N/K    C/Y V   A/G    
BV245 A1 AZT+3TC+EFV 27m 83 180       N             
BV224 - d4T+3TC+NVP 30m 79 515 Sequencing not successful 
BV113 A1 d4T+3TC+EFV 32m 1030 467  N          V       
BV145 A1 d4T+3TC+EFV 33m 294 206       N I    V       
BV223 A1 
d4T+3TC+EFV
ABC+3TC+LPV
18m
1m 1370 188                 V   S     
BV114 CRF16_AD 
d4T+3TC+EFV
AZT+3TC+LPV
34m
1m 15300 217       N            H 
BV120 - 
AZT+3TC+NVP
d4T+3TC+LPV 
41m 
9m 81 226 Sequencing not successful 
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Discussion and future perspectives 
Chapter III: Discussion and future perspectives 
3.1. Discussion 
More than 25 years after the first case of HIV/AIDS and more than 10 years after the 
first use of HAART, the worldwide AIDS epidemic remains a challenge. At the end of 
2007, about 33 million people were living with HIV/AIDS, with nearly 2.5 million newly 
infected yearly [1]. The majority of them reside in Sub-Saharan Africa and Asia. 
Despite worldwide efforts to prevent the HIV spread, the epidemic continues to grow. 
In the last couple of years the delivery of HAART in low and middle-income countries 
has been a public health priority. The World Health Organization (WHO) and the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the ‘3 by 5’ 
initiative in December 2003. This programme aimed at closing the gap between 
those in need of treatment and those receiving it. Substantial progress has been 
made in expanding the provision of treatment in resource-limited settings, although 
results were less optimal than initially hoped for: in June 2006 about 2 million people 
received treatment, which is only 28% of those who need it [75]. This result is 
sobering and encouraging at the same time; decent health care infrastructure, trained 
staff and affordable drug supplies are still lacking in many of these countries, 
nevertheless some resource-limited countries showed that these obstacles can be 
overcome. The new goal now is to get as close as possible to universal access of 
treatment by 2010.  
 
In industrialised countries, CD4+ T cell counts, viral load assays and resistance 
assays are widely recommended and used to monitor HIV-infected patients on 
treatment. Yet, due to limited resources and inadequate laboratory infrastructure in 
most resource-limited countries, laboratory monitoring for patients on treatment has 
been kept to a minimum and priority was given to the improvement of the widespread 
availability of antiretroviral drugs [77]. CD4+ T cell assays, which are important 
laboratory tools to initiate treatment [39] become more widely available in resource-
limited countries, but the supply of reagents remains challenging in most places. 
Although CD4 count is considered as a suboptimal marker for ART monitoring, 
compared to the gold standards of viral load and resistance testing, the current WHO 
recommendation is to switch to a second-line treatment based on clinical or 
immunological failure [39]. This has led to significant misclassification of therapeutic 
responses as was pointed out by some studies [83-87] and a much wider introduction 
 81
Discussion and future perspectives 
of viral load measurements for ART monitoring is urgently needed. This can only be 
implemented if the costs of these assays can be reduced and if technical issues can 
be overcome in resource-limited settings. 
Since delivery of ART in resource-limited countries is expanding, the need for viral 
load assays is increasing [123]. Regular viral load determination allows the early 
recognition of treatment failure and, if necessary, a timely therapy switch to avoid 
accumulation of resistance mutations and development of broad cross-resistance, or 
an early adherence intervention in case of viral load rebounds [45, 46, 124]. This is 
not only important for the individual patient,  the spread of resistant viruses in the 
population can also jeopardise future treatment for recently infected, ART naïve 
patients. Besides using viral load measurements for treatment monitoring, it can also 
be used for the diagnosis of perinatal infections by detection of viral RNA [88-90, 
125] and as a sentinel surveillance tool in ART program quality assessments. To 
achieve these goals, the costs of these assays have to decrease substantially. 
Besides the problem of the high cost of reagents and equipment, the implementation 
of viral load testing in resource-limited settings is often hindered by the lack of decent 
laboratory infrastructure (clean water, electricity, air conditioning etc.), trained lab 
technicians, sample shipment facilities, equipment maintenance service and external 
quality control programs. Although it will be extremely difficult to find an assay that is 
at the same time sensitive, specific, easy to perform and cheap, some alternative 
assays have been developed and evaluated. Schupbach and colleagues were the 
first to suggest an alternative viral load assay by quantitatively measuring p24 Ag [91, 
96, 97, 126]. The ultrasensitive p24 Ag assay (Perkin-Elmer) measures the p24 Ag in 
plasma by a standard ELISA test. The promising results of this simple and cheap 
assay (5-10 USD/test) were confirmed by some [92-95, 98], but others showed a lack 
of correlation between the p24 assay and the standard viral load assays [99-101]. 
Due to conflicting results and the need for an external lysis buffer to increase 
sensitivity, the p24 Ag assay is no longer recommended to monitor patients on 
treatment. However, this assay is suitable for paediatric diagnosis of HIV-infection 
[102-105]. Another non-nucleic acid-based alternative for measuring HIV-1 viral load 
is the ExavirLoad assay (Cavidi), that measures HIV RT enzyme activity by an ELISA 
assay [108]. Correlations between ExavirLoad and FDA approved viral load assays 
seem to be more consistent, including high sensitivity and specificity [98, 109-113, 
127, 128]. A third group of alternative viral load assays are the in-house real-time 
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PCR assays. Lewin et al. were the first to describe such an assay to detect HIV-1 
RNA [114] and others showed that the quantification of HIV-1 RNA by real-time PCR 
was feasible [115-120]. Rouet et al, found their in-house real-time PCR assay to be 
suitable for patient monitoring and paediatric diagnosis in Côte d’Ivoire [119]. Based 
on these good results, a French company (Biocentric) decided to produce ‘Generic 
HIV viral load assay’ to quantify HIV-1 RNA. 
At the moment, the ExavirLoad and a real-time PCR assay, like the Generic HIV viral 
load, seem to be the most promising alternatives for the standard viral load tests. 
Few groups have evaluated these assays in resource-limited settings and most of the 
evaluations were done in collaboration with the manufacturer. The availability of both 
assays in Coast Province General Hospital in Mombasa made us decide to assess 
them in a real-life situation and to compare the results of both assays with the results 
of the standard viral load assay from Roche. We found a good correlation for both 
assays when compared with the Amplicor HIV-1 Monitor v1.5 assay, but the 
specificity was less optimal, especially for the ExavirLoad. As the quantification of 
HIV-1 RNA by ExavirLoad is based on RT enzyme activity little influence of different 
subtypes is expected [108, 110]. However, in our study, a relatively higher number of 
false positive results were seen for subtype C and D. Further analysis was limited 
due to the small sample size and after pooling the non-A subtypes no statistical 
difference between non-A and subtype A could be detected. The Generic HIV-1 viral 
load deals with the HIV-1 diversity challenge by targeting the non-specific LTR region 
[117, 118]. No subtype-related differences in results were detected in our study, 
confirming the suitability of the LTR region for broad subtype specific amplification 
assays. 
Both the Generic HIV viral load assay and the ExaVirLoad assay could be valuable 
tools for viral load determination in resource-limited settings, yet both tests have their 
limitations and should not be implemented without a thorough on-site evaluation. The 
ExavirLoad has the advantage of a low start-up cost (3000 USD) and virtually no 
maintenance requirements, but despite the relatively simple method, the assay is 
time consuming, the cost per test remains relatively high (30 USD/test) and no 
external quality control program has been developed yet. The Generic HIV viral load 
on the other hand, has a low turn-around time, a relatively low cost per test (10-20 
USD) and an established external quality control program (Agence Nationale de 
Recherches sur le SIDA, ANRS Paris), but the assay requires expensive equipment 
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that needs regular servicing. This indicates that the choice for the right viral load 
assay should be made at each site individually, taking the available facilities and 
specific needs into account. Meanwhile manufacturers of commercial viral load 
assays should commit themselves to further simplify their assays, reduce the prices 
and provide the necessary support in infrastructure for the use of their assays in 
resource-limited settings. 
 
Besides viral load assays, current US and European treatment guidelines 
recommend genotypic resistance assays to assess the presence of baseline 
resistance before treatment initiation, and in all cases where treatment failure is 
suspected [36-38]. The information obtained by genotypic resistance assays can 
assist in the selection of the optimal drug regimen. However the high cost and 
complexity of these assays make the tests almost inaccessible in resource-limited 
settings. Moreover, one might argue that the need for drug resistance assays in 
resource-limited settings is not extremely urgent yet, because the expected 
resistance pattern is predictable, when failing the widely used NNRTI-based first-line 
regimens [129, 130] and guidelines recommend to change all components of the 
regimen in case of failure [39]. In reality however, access to second-line drugs 
remains a problem in resource-limited settings. Due to the few ARV drugs available 
in these regions, replacing all the components of the first-line regimen is often 
impossible and recycling drugs in the second regimen remains the only option. In this 
case, the efficiency of the second-line regimen will definitely improve if the choice of 
the medication can be guided by resistance testing. The need for drug resistance 
assays will increase even more when the number of available ARV drugs in 
resource-limited settings increases and when third-line and salvage regimens 
become an option. Because viral load assays and potent second-line regimens are 
not always available, many patients in resource-limited settings will be exposed to 
sub-optimal treatment, increasing the risk of accumulation of resistance mutations 
and the probability of cross-resistance. This will not only pose a problem for the 
individual patient, but also increase the risk of transmission of highly resistant viruses 
in the population. The prevalence of transmitted drug resistance (TDR) in countries 
with established ART programs ranges from 6.0% to 24.1% in the US and Western 
Europe and from 3.1% to 22.2% in Southern America [47]. At the moment the 
prevalence of TDR in resource-limited settings is still low [47], but some fear that the 
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numbers are likely to increase now that ART is more widespread and virological 
failure might only be detected at a later stage. However, due to the absence of mono- 
and bitherpay, the rate of transmitted drug resistance will be lower than that seen in 
the industrialized world. Blower et al. have predicted that the transmission rate of 
drug resistant HIV in resource-limited settings will be below the WHO surveillance 
threshold of 5%, assuming that 10% of the HIV infected population is treated [131]. 
On the other hand, a high proportion of treated cases can be expected to develop 
drug resistance, and therefore it is suggested that sentinel surveillance to monitor 
TDR should mainly be done in a few areas where treatment coverage is high. 
Monitoring the prevalence of drug resistance in treated individuals would be an 
effective strategy to monitor program effectiveness and to asses the public health 
impact of the roll-out of ART on drug resistant HIV [131]. 
This shows that there is a need for affordable genotypic resistance assays and we 
therefore assessed an in-house assay that allows the combined detection of plasma 
HIV-1 and drug resistance. In this assay the protease (PR) and reverse transcriptase 
(RT) gene, two major target genes for antiretroviral therapy, were amplified in a 
highly sensitive nested RT-PCR and subsequently used in a direct sequencing 
procedure. The high sensitivity (100% for samples with a viral load >500 c/ml and 
about 75% for samples with a viral load between 50 and 500 c/ml) indicates that this 
subtype-independent assay can potentially be used as a qualitative viral load assay 
(25 USD/test), reducing the need for a standard viral load assay. Positive PCR 
results, indicating treatment failure, can subsequently be used to detect possible drug 
resistance mutations (40 USD/test). The use of this method for the follow-up of 
patients under treatment will allow fast detection of emerging drug resistance at a 
more affordable price than the commercial tests. 
 
Although the cost of drug resistance assays can be reduced by using in-house 
methods, the need for specialised equipment and proper infrastructure remains. This 
is not only a problem for the assay itself, but also the collection of samples is subject 
to logistical obstacles like storage and transportation in a cold chain. If the need for a 
cold chain can be avoided, samples could easily be collected in the field and then 
sent to a centralised reference laboratory where the required equipment and 
infrastructure are available. Dry blood spots (DBS) are an ideal medium for blood 
collection in the field. A drop of blood can be spotted directly on the filter paper and 
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after air drying the papers can be handled as non-infectious and transported to a 
central laboratory by regular air mail [132]. Moreover, this method of sample 
collection avoids the need for centrifugation, the need for a freezer at the collection 
site and the need for frozen shipment. In the last 25 years DBS have been used for 
various purposes, including detection of HIV antibodies [133-137], detection of HIV 
antigen [138, 139], early diagnosis of perinatally infected infants [140-144], 
quantification of CD4+ T cells [145] and quantification of viral plasma RNA [146-153]. 
Few studies examined the possibility to perform drug resistance testing on dried 
blood, plasma or serum on filter paper[154-156]. Our in-house sequencing method 
for RNA was adapted for the use of DNA from whole blood and DBS. The high 
sensitivity that was found, confirmed the feasibility of extracting and sequencing HIV-
1 DNA from DBS as previously shown by others [156, 157]. Because DNA is a more 
stable molecule compared to RNA and DNA requires less manipulations, its use is 
ideal in resource-limited settings. However, the correlation between drug resistance-
related mutations detected in RNA and DNA remains unclear. Despite the fact that 
most studies found a substantial correlation between DNA and RNA, some studies 
detected more mutations in DNA [158, 159] while others reported more resistance 
mutations in RNA sequences [157, 160-163]. Also in our study, we found more 
mutations in RNA sequences compared to DNA, especially in patients with a 
relatively low viral load. This can be explained by the different kinetics between the 
plasma RNA and the whole blood DNA compartments as the genetic turn-over of 
PBMCs (DNA) is much slower compared to plasma RNA and only a minor subset of 
PBMCs is involved in the HIV replication [16, 17]. As a result, the emergence of 
resistance related mutations in plasma RNA precedes that in DNA and sequencing of 
RNA remains superior in the detection of resistance at early treatment failure. 
Despite the poor correlation between RNA and DNA in our study, sequencing from 
DNA can still be a valuable tool for the detection of mutations selected under 
previous drug regimens [158, 159] and in a more epidemiological approach to 
analyse the HIV subtype distribution and the spread of drug resistance mutations in a 
population.  
 
Despite the lack of accurate laboratory tools to monitor ART treated patients in 
resource-limited settings, the scale-up of ART has been proven successful in these 
regions [129, 164-168]. In our study in Mombasa, the treatment success rate was 
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86.2% for those treated for at least 6 months. Some of the reasons for these 
successful early outcomes are the availability of highly effective HAART for treatment 
naïve patients [76], the low prevalence of primary resistance [47] and the 
unexpectedly high level of treatment compliance [169]. In most resource-limited 
settings, the decision on when to start or switch treatment is solely based on clinical 
and immunological markers [39]. For this reason, patients are likely to remain on a 
failing regimen for a longer period, thereby increasing the risk of accumulating drug 
resistance mutations in the virus, which jeopardizes second-line treatment options 
and which increases the risk of spreading transmitted drug resistance in the 
population. The accumulation of resistance mutations under these circumstances has 
been proven by several groups [129, 166, 170] and was confirmed by our study 
where 87.5% of the patients with a detectable viral load developed drug resistance 
mutations in the RT gene. Due to the low genetic barrier, the development of M184V 
and K103N mutations is predictable under the recommended first-line regimens of 
AZT or d4T with 3TC and NVP or EFV [129, 130]. Nevertheless, it is of great concern 
that more than 60% of the patients with virological failure after a relatively short time 
developed high level resistance against 3TC and the NNRTI class. Moreover, in 
three patients the multi-drug resistant Q151M and K65R mutations were detected. 
This observation will have major implications towards the selection of a potent 
second-line regimen. Ideally, a second-line regimen should consist of at least three 
fully active drugs in order to obtain complete viral suppression [36-38]. In the 
absence of drug resistance assays in resource-limited settings, the best option would 
be to start a second regimen with 3 not previously used drugs, having low cross-
resistance with the drugs that were taken before. At the moment this does not seem 
to be a very feasible option in many resource-limited settings, due to the limited 
availability of second-line drugs. A better accessibility to second-line regimens should 
be a top priority. A Thai study demonstrated that up to 48% of the patients failing 
their first-line regimen have limited options for second-line treatment with the 
currently available drugs in their country [170]. Therefore it is likely that a number of 
drugs will be recycled. Especially the NRTI 3TC is considered to be a possible 
candidate for recycling. Although 3TC has a significantly reduced activity in patients 
harbouring virus with the M184V mutation, some evidence exists that viruses 
harbouring this mutation partly lose their replicative capacity [171] and that partial 
antiviral activity of 3TC is preserved [172, 173]. Moreover, the development of the 
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M184V mutation can resensitize the virus for AZT in case of the presence of the AZT 
resistance mutation 215Y [174]. At this stage, the long term benefits of the M184V 
mutation are less well understood. Nevertheless, when no options for a fully 
suppressive regimen are available, a 3TC-based regimen can be continued. 
Sungkanuparph et al. also indicated that the number of patients failing their first-line 
regimen with limited second-line options increased to 63% among patients with late 
detection of treatment failure and decreased to 30% when treatment failure could be 
detected early [170]. In our study three patients still carried a wild type virus at 
treatment failure (viral load: 55, 533 and 1380 c/ml), after being treated for 
respectively 6, 23 and 26 months. Again this advocates for the implementation of 
viral load assays in order to detect early treatment failure and prevent the 
development of extensive drug resistance as much as possible. Although this 
approach will increase the laboratory costs, it will reserve scarce and expensive 
second-line regimens for those who really need it. 
 
There is still a long way to go in order to improve the treatment and care of HIV 
infected patients. Continuous efforts should be made to further expand the access to 
ART in middle and low-income countries and thereby special attention should be give 
to the monitoring of these patients on treatment. 
While affordable ART becomes gradually more and more available in many resource-
limited settings and the necessity for affordable and field-adapted monitoring tools 
seems to get on the local and international agendas, it is of uttermost importance to 
continue the search for new and the implementation of existing preventive strategies.  
After more than 25 years in the HIV epidemic, it seems that the main preventive tool 
remains the male condom. Given its correct use, this device provides very good 
protection against HIV and other sexually transmitted infections. Unfortunately, it is 
not easy to motivate people to use condoms, and on top of that, the condom is a 
male controlled prevention tool leaving the women in a vulnerable position. Therefore 
there is an urgent need for better preventive strategies. A major success in the field 
of prevention was recently obtained when male circumcision proved to reduce the 
number of new infections by at least 50% in circumcised men [175-177]. 
An HIV vaccine would provide the best solution to prevent the epidemic to spread 
even more, but the chances to find a safe vaccine with good efficacy within the next 
10 years seems to be further away than ever, after the recent closure of the clinical 
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trials for the Merck’s STEP adenovirus-5-based vaccine [178, 179].The development 
of an effective microbicide is another important track to prevent further spread of HIV. 
This prevention method is female-controlled which is an important characteristic. 
Unfortunately, after nonoxynol-9 was found to be ineffective to prevent HIV infection, 
and even possibly harmful when used as a microbicide [180], another possible 
candidate joined the list of failures. Last January, a phase III clinical trial with 
cellulose sulphate was closed early because preliminary results indicated this 
product could potentially lead to an increased risk of HIV acquisition in those women 
using the product. In response another trial using cellulose sulphate in Nigeria was 
stopped as a precaution [181]. Despite this negative signal, there is still hope as 
several other microbicide candidates, using different modes of action, are currently in 
phase II and III clinical trials [182]. 
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3.2. Future perspectives 
The initial doubts about the implementation of ART roll-out in resource-limited 
settings have been proven wrong. Many countries have shown that the logistical 
challenges of public health infrastructure, training of staff and the supply of 
antiretroviral drugs can be overcome, but there still lies a long way ahead of us. The 
need for affordable viral load and genotyping assays is increasing in order to further 
improve the quality of care provided to the majority of HIV-infected individuals. Viral 
load assays are not only useful for detection of early treatment failure, but they can 
also be of great value in monitoring treatment adherence, in the diagnosis of 
perinatally infected children and in general efficacy assessments of ART roll-out 
programs. The simple and cheaper alternative viral load assays that are currently on 
the market still have their specific limitations including sensitivity/specificity, high 
start-up costs, need for specialised equipment and trained personnel. Moreover, their 
use in the follow-up of patients on treatment should be further evaluated. 
Furthermore, the continuous search for less complicated and low-cost alternatives 
based on dipstick technology [183], micro-arrays [184] or molecular zipper [185] are 
of extreme importance. Ideally, new viral load assays should be so simple that they 
can be used in district health care settings. Meanwhile, companies marketing viral 
load assays should make an effort to reduce prices for their tests in resource-limited 
settings. 
Even if viral load assays would become more readily available and early treatment 
failure can easily be detected, the development of drug resistance is inevitable. 
Therefore the need for genotypic resistance assays is also important. Options for 
simultaneous detection of viral load and possible resistance mutations, like our in-
house method, should be further explored. The implementation of our in-house 
genotyping assay should be evaluated in a resource-limited setting such as 
Mombasa because the combined detection of possible virological failure and 
subsequent identification of potential drug resistance mutations is a promising 
strategy. In this respect we could set-up a study whereby patients on ART are 
monitored using two systems: first, the standard follow-up system (standard viral load 
assay and subsequent genotyping in case of a detectable viral load) and secondly, 
our in-house genotyping assay whereby the qualitative amplification step replaces 
the standard viral load assay. When this in-house genotyping system proves to be 
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equally useful in the monitoring of patients on treatment, the implementation of this 
assay in a resource-limited setting, such as Mombasa, should be evaluated. 
The optimisation of genotypic resistance assays on RNA and DNA extracted from dry 
blood spots deserves more attention as its use would simplify sample collection on 
site and sample shipment to central laboratories. 
 
But let us not make the perfect the enemy of the good. Despite the limited availability 
of adequate laboratory tools to monitor patients on treatment and the relatively high 
rate of resistance among patients failing treatment, the roll-out of ART in resource-
limited settings should be continued in order to close the gap between the many in 
need of treatment and the few who actually have access to it. Continuous monitoring 
of ART programs in terms of treatment success and development of resistance 
should be used for future adaptations of treatment strategies and more ARV drugs 
should be generically made available in resource-limited areas, including newly 
developed drugs. 
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